Preparation of peptide inhibitor of interleukin-23 receptor and use thereof

MYPI2025006849A0Undetermined Publication Date: 2024-11-04TIBET HAISCO PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025006849
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-13
Filing Date
2024-04-30
Publication Date
2024-11-04

AI Technical Summary

Technical Problem

Existing technologies struggle to target the IL-23 pathway, resulting in a lack of effective drugs for the treatment and prevention of IL-23-related diseases such as inflammatory bowel disease and psoriasis. In particular, the development of selective drugs targeting the intestinal lumen presents significant challenges.

Method used

A novel peptide inhibitor has been developed that specifically binds to the IL-23 receptor, inhibits IL-23 signal transduction, and exhibits protein stability and a long plasma half-life, making it suitable for oral administration.

Benefits of technology

This peptide inhibitor can effectively inhibit IL-23 signaling, providing therapeutic benefits for IL-23-related diseases, especially inflammatory bowel disease and psoriasis, and has good pharmacokinetic and pharmacodynamic properties.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided are a new peptide inhibitor of an interleukin-23 receptor, a stereoisomer or pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing same, and the use of the peptide inhibitor in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease, psoriasis, etc.
Need to check novelty before this filing date? Find Prior Art

Description

Preparation and use of peptide inhibitors of interleukin-23 receptor Technical Field

[0001] The present invention relates to novel peptide inhibitors of the interleukin-23 receptor and their use in treating or preventing a variety of diseases and conditions, including inflammatory bowel disease, Crohn's disease and psoriasis. Background Art

[0002] The interleukin-23 (IL-23) cytokine has been implicated as a key player in the pathogenesis of autoimmune diseases such as multiple sclerosis, asthma, rheumatoid arthritis, psoriasis, and inflammatory bowel disease (IBD). Studies in mouse models of acute and chronic IBD have demonstrated that IL-23R and downstream effector cytokines play a major role in disease pathogenesis. IL-23R is expressed on a variety of adaptive and innate immune cells, including Th17 cells, γδT cells, natural killer (NK) cells, dendritic cells, macrophages, and innate lymphocytes, which are abundant in the intestine. IL-23R gene expression and protein levels have been found to be elevated in patients with IBD at the intestinal mucosal surface. IL-23 is thought to mediate this effect by promoting the development of pathogenic CD4+ T cell populations that produce IL-6, IL-17, and tumor necrosis factor (TNF).

[0003] The produced IL-23 is enriched in the intestine, where it plays a key role in regulating the balance between tolerance and immunity through T cell-dependent and T cell-independent inflammatory pathways by acting on T helper 1 (Th1) and Th17-related cytokines and inhibiting regulatory T cell responses in the intestine (which promote inflammation). In addition, polymorphism of the IL-23 receptor (IL-23R) has been associated with susceptibility to inflammatory bowel disease (IBD), further establishing the key role of the IL-23 pathway in intestinal homeostasis.

[0004] Psoriasis is a chronic skin disease affecting 2% to 3% of the population and has been shown to be mediated by the body's T-cell inflammatory response mechanism. IL-23, one of several interleukins, is considered a key player in the pathogenesis of psoriasis, allegedly maintaining chronic autoimmune inflammation through induction of interleukin-17, regulation of memory T cells, and activation of macrophages. Expression of IL-23 and IL-23R has been shown to be increased in tissues from psoriasis patients, and antibodies neutralizing IL-23 have demonstrated IL-23-dependent inhibition of psoriasis progression in animal models of psoriasis.

[0005] IL-23 is a heterodimer composed of a unique p19 subunit and the p40 subunit of IL-12. It is a T helper cell 1 (TH1) developmental cytokine involved in the production of interferon-γ (IFN-γ). Although both IL-23 and IL-12 contain the p40 subunit, they have different phenotypic properties. For example, IL-12-deficient animals are susceptible to inflammatory autoimmune diseases, while IL-23-deficient animals are resistant, presumably because the number of CD4+ T cells producing IL-6, IL-17, and TNF in the CNS of IL-23-deficient animals is reduced. IL-23 binds to IL-23R, a heterodimeric receptor composed of IL-12Rβ1 and IL-23R subunits. IL-23 binding to the IL-23R activates Jak-stat signaling molecules, including Jak2 and Tyk2, as well as Stat1, Stat3, Stat4, and Stat5. Stat4 activation is substantially weaker, and distinct DNA-bound Stat complexes are formed in response to IL-23 compared to IL-12. IL-23R constitutively binds to Jak2 and to Stat3 in a ligand-dependent manner. In contrast to IL-12, which primarily acts on naive CD4(+) T cells, IL-23 preferentially acts on memory CD4(+) T cells.

[0006] Therapeutic moieties that inhibit the IL-23 pathway have been identified for the treatment of IL-23-related diseases. A large number of antibodies that bind to IL-23 or IL-23R have been identified, including ustekinumab (a humanized antibody that binds to IL-23), which has been approved for the treatment of psoriasis. Peptide inhibitors that bind to IL-23R and inhibit the binding of IL-23 to IL-23R have recently been identified. Clinical trials of Crohn's disease or psoriasis with ustekinumab and briakinumab (which target the common p40 subunit) and tildrakizumab, guselkumab, MEDI2070 and BI-655066 (which target the unique p19 subunit of IL-23) have highlighted the potential of blocking IL-23 signal transduction in the treatment of human inflammatory diseases. While these findings are promising, challenges remain regarding the identification of stable and selective agents that preferentially target the IL-23 pathway in the intestine, which could be used to treat intestinal inflammatory diseases, including Crohn's disease, ulcerative colitis, and related disorders.

[0007] Therefore, there remains a need in the art for new therapies targeting the IL-23 pathway that can be used to treat and prevent IL-23-related diseases, including those associated with autoimmunity. Furthermore, compounds and methods that specifically target the IL-23R from the intestinal lumen could provide therapeutic benefits for patients with IBD. The present invention addresses these needs by providing novel peptide inhibitors that bind to IL-23R to inhibit IL-23 binding and signaling, and are suitable for oral administration.

[0008] Summary of the Invention

[0009] The present invention discloses a novel peptide inhibitor of interleukin-23 receptor, its stereoisomers or pharmaceutically acceptable salts or solvates, or pharmaceutical compositions containing them, and uses of the peptide inhibitor in treating or preventing diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

[0010] The peptide compound of the present invention has protein stability and is stable to plasma proteases, epithelial proteases, gastric and intestinal proteases, lung surface proteases, intracellular proteases, etc.; has specific targeting to IL-23; has a long plasma half-life, and has good pharmacokinetic and pharmacodynamic properties.

[0011] The present invention relates to a cyclic peptide compound, a stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, or dimer thereof, wherein the peptide compound has an amino acid sequence of formula (I), formula (II), formula (II-1), formula (III), formula (III-1), formula (IV), formula (IV-1), or formula (V):

[0012] Xa1-Xa2-Xa3-Xa4-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Xa 11 -Xa 12 -Xa 13 (I)

[0013] (Ac)Xa1-Xa2-Thr-Xa4-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Asn-(3-Pal)-Sarc(NH2) (II)

[0014] (Ac)Xa1-Xa2-Thr-Xa4-Lys(Ac)-Xa6-Xa7-Xa8-Xa9-Glu-Asn-(3-Pal)-Sarc(NH2) (II-1)(SEQ ID NO.1)

[0015] (Ac)Xa1-Xa2-Thr-Trp(R1)-Xa5-Xa6-Xa7-Xa8-Xa9-Xa10 -Asn-(3-Pal)-sarc(NH2) (III)

[0016] (Ac)Xa1-Xa2-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-Xa8-Xa9-Glu-Asn-(3-Pal)-Sarc(NH2) (III-1)(SEQ ID NO.2)

[0017] (N-terminal)Xa1-Asn-Thr-Trp(R1)-Xa5-Xa6-Xa7-(2-Nal)-Xa9-Xa 10 -Xa 11 -Xa 12 -Sarc(C-terminus) (IV)

[0018] (N-terminal)Xa1-Asn-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-(2-Nal)-Xa9-Glu-Xa 11 -Xa 12 -Sarc(C-terminal) (IV-1)(SEQ ID NO.3)

[0019] (N-terminal)Xa1-His-Thr-Trp(R1)-Xa5-Xa6-Xa7-(2-Nal)-Xa9-Xa 10 -Xa 11 -Xa 12 -Sarc(C-terminal) (V)

[0020] Alternatively, the peptide compound is a dimer compound, wherein the dimer compound is formed by linking the peptide compound and the amino acid residues in the peptide compound via a polyethylene glycol chain; the polyethylene glycol chain is

[0021] n is any integer selected from 0-99;

[0022] Alternatively, the peptide compound is optionally conjugated with a modifying group at Xa1 or at Xa5;

[0023] Alternatively, the peptide compound is optionally conjugated with a modifying group at Xa1, Xa5 or Xa7;

[0024] In some embodiments, the modifying group is p is selected from any integer between 0 and 50, q is selected from any integer between 0 and 50

[0025] In some embodiments, the modifying group is p is selected from any integer between 0 and 50, q is selected from any integer between 0 and 50;

[0026] In some embodiments, the modifying group is

[0027] Wherein, p is selected from any integer between 0 and 5, and q is selected from any integer between 0 and 5;

[0028] In some embodiments, the modifying group is

[0029] In some embodiments, p is 1 and q is 2;

[0030] wherein Xa1 and Xa6 are each independently selected from Pen, Pcn, Asn, Ala, Ala(3-amino), Ala(2-ethyne), Ala(3-azido), Ala(2-ethene), Val(2-ethene), Asp, 2,4-diaminobutyric acid, Ser, Cys, Hcys, and Glu, and the residues of Xa1 and Xa6 react to form a peptide ring or form a cyclic peptide via L1;

[0031] In some embodiments, Xa1 and Xa6 are each independently selected from Pen, Asn, Ala, Ala (3-amino), Ala (2-ethyne), Ala (3-azido), Ala (2-ethene), Val (2-ethene), Asp, 2,4-diaminobutyric acid, Ser, Cys, Hcys, Glu, and the residues of Xa1 and Xa6 react to form a peptide ring;

[0032] In some embodiments, Xa1 and Xa6 are each independently selected from Pen, Asn, Ala, Ala (3-amino), Ala (2-ethyne), Ala (3-azido), Ala (2-ethene), Val (2-ethene), and the residues of Xa1 and Xa6 react to form a peptide ring;

[0033] Among them, the residues of Xa1 and Xa6 preferably form a peptide ring through a condensation reaction, an RCM ring-closure reaction, or the like;

[0034] In some embodiments, Xa1, Xa6 are selected from Pen;

[0035] In some embodiments, Xa1 and Xa6 are each independently selected from Asn or Ala(3-amino);

[0036] In some embodiments, Xa1 is selected from Asn, Xa6 is selected from Ala(3-amino);

[0037] In some embodiments, Xa1 and Xa6 are each independently selected from Ala (2-ethyne) or Ala (3-azido);

[0038] In some embodiments, Xa1 is selected from Ala(3-azido), Xa6 is selected from Ala(2-ethyne);

[0039] In some embodiments, Xa1, Xa6 are selected from Val(2-ethene);

[0040] In some embodiments, Xa1, Xa6 are selected from Ala (2-ethene);

[0041] In some embodiments, Xa1 and Xa6 are each independently selected from Asp or Ala (3-amino);

[0042] In some embodiments, Xa1 and Xa6 are selected from 2,4-diaminobutyric acid;

[0043] In some embodiments, Xa1 and Xa6 are each independently selected from 2,4-diaminobutyric acid or Asp;

[0044] In some embodiments, Xa1 and Xa6 are each independently selected from Ser or Ala (3-amino);

[0045] In some embodiments, Xa1 and Xa6 are each independently selected from 2,4-diaminobutyric acid or Ser;

[0046] In some embodiments, Xa1, Xa6 are selected from Ala(3-amino);

[0047] In some embodiments, Xa1 and Xa6 are each independently selected from Cys or Asp;

[0048] In some embodiments, Xa1 and Xa6 are each independently selected from Glu or Ala (3-amino);

[0049] In some embodiments, Xa1 and Xa6 are each independently selected from Hcys or Asp;

[0050] In some embodiments, the residues Xa1 and Xa6 react to form the following structure:

[0051] In some embodiments, the residues Xa1 and Xa6 react to form the following structure:

[0052] In some embodiments, the residues Xa1 and Xa6 react to form the following structure:

[0053] The * end is the Xa1 end, Xa1 and Xa2 are connected through the * position, and the NH2 end is connected to the protecting group;

[0054] Or the * end is the Xa1 end, Xa1 and Xa2 are connected through the * position, and the NH2 end is conjugated with a modifying group;

[0055] In some embodiments, the NH2-terminus conjugated modifying group is selected from

[0056] In some embodiments, the NH2-terminus conjugated modifying group is selected from

[0057] Xa2 is selected from Asn, His, or analogs of Asn and His;

[0058] In some embodiments, Xa2 is selected from Asn;

[0059] In some embodiments, Xa2 is selected from Asn, His, or an analog of His selected from

[0060] In some embodiments, Xa2 is selected from Asn, His, or an analog of His selected from

[0061] In some embodiments, Xa2 is selected from Asn or an analog of His selected from

[0062] Xa3 is selected from Thr or an analog of Thr;

[0063] In some embodiments, Xa3 is selected from Thr;

[0064] Xa4 is selected from Trp or an analog of Trp;

[0065] In some embodiments, Xa4 is selected from an analog of Trp selected from

[0066] Xa5 is selected from Lys, Gln, Arg, Cit, or an analog of Lys, Gln, Cit, Arg; alternatively, the Xa5 residue is conjugated to a modifying group;

[0067] Xa5 is selected from Lys, Gln, Arg, Cit, or an analog of Lys, Gln, Cit, or Arg;

[0068] In some embodiments, Xa5 is selected from Lys, Gln, Arg, Cit, or an analog of Arg selected from

[0069] In some embodiments, Xa5 is selected from Lys, Gln, Arg, or an analog of Lys, Gln, and Arg;

[0070] In some embodiments, Xa5 is selected from Lys, Gln, Arg, or an analog of Lys or Arg;

[0071] In some embodiments, Xa5 is selected from Lys or an analog of Lys;

[0072] In some embodiments, Xa5 is selected from Lys;

[0073] In some embodiments, Xa5 is selected from Lys, Gln, Arg, or an analog of Lys or Arg; the analog of Arg or Lys is selected from In some embodiments, Xa5 is selected from Lys, Gln, Arg or an analog of Arg selected from

[0074] In some embodiments, the modifying group to which the Xa5 residue is conjugated is selected from

[0075] In some embodiments, the modifying group to which the Xa5 residue is conjugated is selected from

[0076] Xa7 is selected from Phe or a Phe analog; alternatively, the Xa7 residue is conjugated to a modifying group;

[0077] Xa7 is selected from Phe or an analog of Phe;

[0078] In some embodiments, Xa7 is selected from Phe or an analog of Phe selected from

[0079] In some embodiments, Xa7 is selected from Phe or an analog of Phe selected from

[0080] In some embodiments, Xa7 is selected from Phe or an analog of Phe selected from

[0081] In some embodiments, the modifying group to which the Xa7 residue is conjugated is selected from

[0082] Xa8 is selected from Phe, Trp, 2-Nal, or analogs of Phe, Trp and 2-Nal;

[0083] In some embodiments, Xa8 is selected from Phe, Trp, 2-Nal, or analogs of Phe, Trp and 2-Nal; wherein the analogs of Phe, Trp and 2-Nal are selected from

[0084] In some embodiments, Xa8 is selected from Phe, Trp, 2-Nal, or analogs of Phe, Trp and 2-Nal; wherein the analogs of Phe, Trp and 2-Nal are selected from

[0085] In some embodiments, Xa8 is selected from Phe, Trp, 2-Nal or an analog of Phe, Trp and 2-Nal; wherein the analog of Phe, Trp and 2-Nal is selected from

[0086] Xa9 is selected from Thp or an analog of Thp;

[0087] In some embodiments, Xa9 is selected from Thp or an analog of Thp selected from

[0088] In some embodiments, Xa9 is selected from Thp or an analog of Thp selected from

[0089] XA 10 Selected from Glu, Cys or analogs of Glu and Cys;

[0090] In some embodiments, Xa 10 Selected from Glu or Glu analogs;

[0091] In some embodiments, Xa 10 Selected from Glu;

[0092] In some embodiments, Xa 10 Selected from Glu or Cys;

[0093] XA 11 Selected from Asn, Lys, or analogs of Asn and Lys;

[0094] In some embodiments, Xa 11 Selected from Asn or Lys;

[0095] In some embodiments, Xa 11 Selected from Asn;

[0096] In some embodiments, Xa 11 Selected from Lys;

[0097] XA 12 Selected from 3-Pal, Phe, Asp, or analogs of 3-Pal, Phe and Asp;

[0098] In some embodiments, Xa 12 Selected from 3-Pal or Phe;

[0099] XA 13 Selected from Sarc or an analog of Sarc;

[0100] In some embodiments, Xa 13 Selected from Sarc;

[0101] Alternatively, Xa1, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa 10 、Xa 11 、Xa 12 、Xa 13 Any amino acid residues in are directly condensed or linked via L1 to form one or more peptide rings;

[0102] In some embodiments, Xa1, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa 10 、Xa 11 、Xa 12 、Xa 13 Any amino acid residues in are linked through L1 to form a peptide ring;

[0103] In some embodiments, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa 10 、Xa 11 、Xa12 、Xa 13 Any amino acid residues in are linked through L1 to form a peptide ring;

[0104] In some embodiments, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa 10 、Xa 11 、Xa 12 、Xa 13 Any two amino acid residues in are linked by L1 to form a peptide ring;

[0105] In some embodiments, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa 10 、Xa 11 、Xa 12 、Xa 13 Any three amino acid residues in are linked through L1 to form a peptide ring;

[0106] Alternatively, the polypeptide is reacted with reactive groups Xa1, Xa6, Xa 10 Separated by covalent bonds formed with the molecular scaffold to form a polypeptide ring containing at least two rings;

[0107] In some embodiments, 2-Nal and Xa 12 The residues are linked by L1 to form a peptide loop; and / or

[0108] Xa9 and Xa 12 The residues are linked by L1 to form a peptide loop; and / or

[0109] Lys(Ac) and Xa7 residues are linked via L1 to form a peptide ring; and / or

[0110] Xa7 vs. Xa 11 The residues are linked by L1 to form a peptide loop; and / or

[0111] The residues of 2-Nal and Glu are linked via L1 to form a peptide ring; and / or

[0112] The residues Xa1 and Glu are linked via L1 to form a peptide ring; and / or

[0113] Xa1 and Xa 10 The residues are linked by L1 to form a peptide loop; and / or

[0114] Xa1 and Xa 11 The residues are linked by L1 to form a peptide loop; and / or

[0115] The residues of 2-Nal and Sarc are linked to form a peptide ring via L1; and / or

[0116] Xa9 and Sarc residues are linked via L1 to form a peptide loop; and / or

[0117] XA 11 The residues of Sarc are linked via L1 to form a peptide loop; and / or

[0118] The residues of Xa1, Sarc, and Glu are linked by L1 to form a peptide ring;

[0119] In some embodiments, the residues of Xa1 and Glu are linked via L1 to form a peptide ring. 11 The residues of Sarc are linked via L1 to form a peptide loop;

[0120] In some embodiments, Trp (R1) and the residues of Xa5 are linked via L1 to form a peptide ring;

[0121] R1 is selected from H, C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-8 membered heterocycloalkyl, said alkyl, cycloalkyl, heterocycloalkyl optionally further substituted by 1-4 groups selected from halogen, =O, C 1-4 Alkyl, halogenated C 1-4 Substitution with alkyl, CN, OH and NH2 substituents;

[0122] In some embodiments, R1 is selected from C 1-2 Alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally further substituted with 1-4 substituents selected from F, Cl, Br, =O, methyl, ethyl, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2F, -CHF2, -CF3, CN, OH and NH2;

[0123] In some embodiments, the residues of Trp (CH3) and Lys (Ac) are linked via L1 to form a peptide ring;

[0124] In some embodiments, 2-Nal and Xa 12 The residues are linked by L1 to form a peptide ring;

[0125] In some embodiments, Xa9 and Xa 12 The residues are linked by L1 to form a peptide ring;

[0126] In some embodiments, Lys (Ac) and the residues of Xa7 are linked via L1 to form a peptide loop;

[0127] In some embodiments, Xa7 and Xa 11The residues are linked by L1 to form a peptide ring;

[0128] In some embodiments, the residues of Xa1 and Glu are linked via L1 to form a peptide ring;

[0129] In some embodiments, Xa1 and Xa 10 The residues are linked by L1 to form a peptide ring;

[0130] In some embodiments, Xa1 and Xa 11 The residues are linked by L1 to form a peptide ring;

[0131] In some embodiments, the residues of 2-Nal and Sarc are linked to form a peptide ring via L1;

[0132] In some embodiments, Xa9 and the residues of Sarc are linked via L1 to form a peptide loop;

[0133] In some embodiments, Xa 11 The residues of Sarc are linked via L1 to form a peptide loop;

[0134] In some embodiments, the residues of Xa1, Sarc, and Glu are linked via L1 to form a peptide ring;

[0135] In some embodiments, the residues of Xa1 and Xa6 react to form a peptide ring; and the residues of Trp (R1) and Xa5 are directly condensed or linked via L1 to form a peptide ring;

[0136] In some embodiments, the residues of Trp (CH3) and Lys (Ac) are directly condensed or linked via L1 to form a peptide ring;

[0137] L1 is selected from W1-R L -W2;

[0138] R L Selected from bond, C 1-6 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 6-10 membered aryl, -(OCH2CH2) a -, the alkylene, alkenylene, alkynylene, cycloalkyl, heterocycloalkyl, heteroaryl, aryl may be further substituted by 1-4 R L1 replace;

[0139] In some embodiments, R L Selected from bond, C 1-6 Alkylene, C 2-4 Alkenylene, C 2-4Alkyne, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 6-10 membered aryl, wherein the alkylene, alkenylene, alkynylene, cycloalkyl, heterocycloalkyl, heteroaryl, aryl are optionally further substituted by 1-4 R L1 replace;

[0140] R L1 are independently selected from halogen, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 1-4 Alkoxy, 3-6 membered cycloalkyl, COOH, NH2, -NH-C(=O)-C 1-4 Alkyl, wherein the alkyl, alkoxy, and cycloalkyl groups are optionally further substituted with 1 to 4 substituents selected from halogen, CN, OH, and NH2;

[0141] In some embodiments, R L1 are independently selected from halogen, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 1-4 Alkoxy, 3-6 membered cycloalkyl, COOH, NH2, wherein the alkyl, alkoxy, and cycloalkyl groups are optionally further substituted with 1-4 substituents selected from halogen, CN, OH, and NH2;

[0142] W1 and W2 are each independently selected from a bond, C 1-6 Alkylene, -O-, -S-, -NR W1 -、-CONR W1 -、-NR W1 CO-, -C(=O)O- or -OC(=O)-, wherein one or more -CH2- in the alkylene group is optionally replaced by 1-4 groups selected from -O-, -S-, -NR W1 - or -CO-, the alkylene group is optionally further substituted by 1-4 groups selected from halogen, =O, C 1-4 Alkyl, halogenated C 1-4 Substitution with alkyl, CN, OH and NH2 substituents;

[0143] R W1 Selected from H, C 1-4 Alkyl, halogen;

[0144] In some embodiments, L1 is selected from a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2) r-NH-, -C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -、-C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-, C 1-6 Alkylene, -C(=O)-, -C(=O)-(CH2) r -NH-, -(CH2) r -O-(CH2) r -NH-, -O-(CH2) r -O-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-, -(CH2) r -NH-C(=O)-(CH2) r -、-C(=O)-(CH2)-(OCH2CH2) a -NH-;

[0145] In some embodiments, L1 is selected from a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -O-(CH2)r -、-C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-, C 1-2 Alkylene, -C(=O)-, -C(=O)-(CH2) r -NH-, -(CH2) r -O-(CH2) r -NH-, -O-(CH2) r -O-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-;

[0146] In some embodiments, L1 is selected from a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -、-C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r-NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-, C 1-2 Alkylene, -C(=O)-, -C(=O)-(CH2) r -NH-, -(CH2) r -O-(CH2) r -NH-, -O-(CH2) r -O-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -(CH2) r -NH-;

[0147] In some embodiments, L1 is selected from a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -、-C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-, C1-2 Alkylene, -C(=O)-, -C(=O)-(CH2) r -NH-,

[0148] In some embodiments, L1 is selected from a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -、-C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-, C 1-2 Alkylene, -C(=O)-(CH2) r -NH-,

[0149] In some embodiments, L1 is selected from a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -、-C(=O)-(CH2)r -O-(CH2) r -O- (CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-, C 1-2 Alkylene, -C(=O)-(CH2) r -NH-,

[0150] r is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0151] In some embodiments, r is selected from 0, 1, 2, 3, 4, or 5;

[0152] In some embodiments, r is selected from 0, 1, 2, or 3;

[0153] a is any integer selected from 0-10;

[0154] In some embodiments, a is selected from 1, 2, 3, 4, 5, or 6;

[0155] In some embodiments, a is selected from 3, 4, 5, or 6;

[0156] and the peptide compound is optionally linked to a protecting group;

[0157] The protecting group is selected from Ac, glutaryl, succinyl, NH2 or OH;

[0158] Unless otherwise specified, the protecting groups Ac, glutaryl, and succinyl described in the present invention are connected to the N-terminus of the amino acid; the protecting groups NH2 and OH are connected to the C-terminus of the amino acid;

[0159] In some embodiments, protecting groups are present or absent at the N-terminus and the C-terminus;

[0160] In some embodiments, there are protecting groups at the N-terminus and the C-terminus, and the protecting groups are selected from Ac or NH2;

[0161] In some embodiments, there is no protecting group at the N-terminus and the C-terminus, provided that: (1) when Xa1 at the N-terminus is linked to other amino acid residues via L1, there is no protecting group at the N-terminus;

[0162] (2) When the C-terminal Sarc is linked to other amino acid residues through L1, the C-terminal protecting group does not exist; alternatively, the polypeptide is protected by reactive groups Xa1, Xa6, Xa 10 Separated by covalent bonds formed with the molecular scaffold to form a polypeptide ring containing at least two rings;

[0163] In some embodiments, the molecular scaffold is selected from:

[0164] In some embodiments, the molecular scaffold is selected from:

[0165] Provided that: the peptide compound is not selected from the following structure: (Ac)Pen-Asn-Thr-Trp(CH3)-Lys(Ac)-Pen-Phe[4-(2-aminoethoxy)]-[2-Nal]-Thp-Glu-Asn-[3-Pal]-Sarc(NH2), wherein a disulfide bond is formed between Pen and Pen.

[0166] As a more specific first technical solution of the present invention, the present invention provides a cyclic peptide compound, a stereoisomer thereof, or a pharmaceutically acceptable salt or solvate or dimer thereof, wherein the peptide compound has an amino acid sequence of formula (I):

[0167] Xa1-Xa2-Xa3-Xa4-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Xa 11 -Xa 12 -Xa 13 (I)

[0168] wherein Xa1 and Xa6 are each independently selected from Pen, Pcn, Asn, Ala, Ala (3-amino), Ala (2-ethyne), Ala (3-azido), Ala (2-ethene), Val (2-ethene), Asp, 2,4-diaminobutyric acid, Ser, Cys, Hcys, and Glu, and the residues of Xa1 and Xa6 react to form a peptide ring or form a cyclic peptide via L1; in some embodiments, Xa1 and Xa6 are each independently selected from Pen, Asn, Ala, Ala (3-amino), Ala (2-ethyne), Ala (3-azido), Ala (2-ethene), Val (2-ethene), Asp, 2,4-diaminobutyric acid, Ser, Cys, Hcys, and Glu, and the residues of Xa1 and Xa6 react to form a peptide ring;

[0169] Xa2 is selected from Asn, His, or an analog of Asn or His;

[0170] Xa3 is selected from Thr or an analog of Thr;

[0171] Xa4 is selected from Trp or an analog of Trp;

[0172] Xa5 is selected from Lys, Gln, Arg, Cit, or an analog of Lys, Gln, Cit, or Arg;

[0173] Xa7 is selected from Phe or an analog of Phe;

[0174] Xa8 is selected from Phe, Trp, 2-Nal, or an analog of Phe, Trp, or 2-Nal;

[0175] Xa9 is selected from Thp or an analog of Thp;

[0176] XA 10 Selected from Glu, Cys, or analogs of Glu and Cys;

[0177] XA 11 Selected from Asn, Lys, or analogs of Asn or Lys;

[0178] XA 12 Selected from 3-Pal, Phe, Asp, or analogs of 3-Pal, Phe, Asp;

[0179] XA 13 Selected from Sarc or an analog of Sarc;

[0180] Alternatively, Xa1, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa10 、Xa 11 、Xa 12 、Xa 13 Any amino acid residues in are directly condensed or linked via L1 to form one or more peptide rings;

[0181] L1 is selected from W1-R L -W2;

[0182] R L Selected from bond, C 1-6 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 6-10 membered aryl, -(OCH2CH2) a -, the alkylene, alkenylene, alkynylene, cycloalkyl, heterocycloalkyl, heteroaryl, aryl may be further substituted by 1-4 R L1 Substitution; in some embodiments, R L Selected from bond, C 1-6 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 6-10 membered aryl, wherein the alkylene, alkenylene, alkynylene, cycloalkyl, heterocycloalkyl, heteroaryl, aryl are optionally further substituted by 1-4 R L1 replace;

[0183] a is any integer selected from 0-10;

[0184] R L1 are independently selected from halogen, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 1-4 Alkoxy, 3-6 membered cycloalkyl, COOH, NH2, -NH-C(=O)-C 1-4 Alkyl, wherein the alkyl, alkoxy, and cycloalkyl groups are optionally further substituted with 1 to 4 substituents selected from halogen, CN, OH, and NH2;

[0185] W1 and W2 are each independently selected from a bond, C 1-6 Alkylene, -O-, -S-, -NR W1 -、-CONR W1 -、-NR W1 CO-, -C(=O)O- or -OC(=O)-, wherein one or more -CH2- in the alkylene group is optionally replaced by 1-4 groups selected from -O-, -S-, -NR W1 - or -CO-, the alkylene group is optionally further substituted by 1-4 groups selected from halogen, =O, C 1-4Alkyl, halogenated C 1-4 Substitution with alkyl, CN, OH and NH2 substituents;

[0186] R W1 Selected from H, C 1-4 Alkyl, halogen;

[0187] and the peptide compound is optionally linked to a protecting group;

[0188] The protecting group is selected from Ac, glutaryl, succinyl, NH2 or OH;

[0189] Alternatively, the polypeptide is reacted with reactive groups Xa1, Xa6, Xa 10 Separated by covalent bonds formed with the molecular scaffold to form a polypeptide ring containing at least two rings;

[0190] Alternatively, the peptide compound is optionally conjugated to a modifying group at Xa1 or at Xa5; or alternatively, the peptide compound is optionally conjugated to a modifying group at Xa1, Xa5 or Xa7;

[0191] Provided that: the peptide compound is not selected from the following structure: (Ac)Pen-Asn-Thr-Trp(CH3)-Lys(Ac)-Pen-Phe[4-(2-aminoethoxy)]-[2-Nal]-Thp-Glu-Asn-[3-Pal]-Sarc(NH2), wherein a disulfide bond is formed between Pen and Pen.

[0192] Furthermore, the peptide compound has an amino acid sequence of formula (I):

[0193] Xa1-Xa2-Xa3-Xa4-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Xa 11 -Xa 12 -Xa 13 (I)

[0194] wherein Xa1 and Xa6 are each independently selected from Pen, Asn, Ala, Ala(3-amino), Ala(2-ethyne), Ala(3-azido), Ala(2-ethene), Val(2-ethene), Asp, 2,4-diaminobutyric acid, Ser, Cys, Hcys, and Glu, and the residues of Xa1 and Xa6 react to form a peptide ring;

[0195] Xa2 is selected from Asn, His, or analogs of Asn and His;

[0196] Xa3 is selected from Thr or an analog of Thr;

[0197] Xa4 is selected from Trp or an analog of Trp;

[0198] Xa5 is selected from Lys, Gln, Arg, Cit, or an analog of Lys, Gln, Cit, Arg; in some embodiments, Xa5 is selected from Lys, Gln, Arg, or an analog of Lys, Gln, Arg;

[0199] Xa7 is selected from Phe or an analog of Phe;

[0200] Xa8 is selected from Phe, Trp, 2-Nal, or an analog of Phe, Trp, or 2-Nal;

[0201] Xa9 is selected from Thp or an analog of Thp;

[0202] XA 10 Selected from Glu, Cys, or analogs of Glu and Cys;

[0203] XA 11 Selected from Asn, Lys, or analogs of Asn or Lys;

[0204] XA 12 Selected from 3-Pal, Phe, Asp, or analogs of 3-Pal, Phe, Asp;

[0205] XA 13 Selected from Sarc or an analog of Sarc;

[0206] Alternatively, Xa1, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa 10 、Xa 11 、Xa 12 、Xa 13 The residues of any amino acids in are directly condensed or linked via L1 to form one or more peptide rings; in some embodiments, Xa1, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa 10 、Xa 11 、Xa 12 、Xa 13 Any amino acid residues in are linked through L1 to form one or more peptide rings;

[0207] L1 is selected from W1-R L -W2;

[0208] R L Selected from bond, C 1-6 Alkylene, C 2-4 Alkenylene, C 2-4Alkyne, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 6-10 membered aryl, wherein the alkylene, alkenylene, alkynylene, cycloalkyl, heterocycloalkyl, heteroaryl, aryl are optionally further substituted by 1-4 R L1 replace;

[0209] R L1 are independently selected from halogen, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 1-4 Alkoxy, 3-6 membered cycloalkyl, COOH, NH2, -NH-C(=O)-C 1-4 Alkyl, wherein the alkyl, alkoxy, and cycloalkyl groups are optionally further substituted with 1 to 4 substituents selected from halogen, CN, OH, and NH2;

[0210] W1 and W2 are each independently selected from a bond, C 1-6 Alkylene, -O-, -S-, -NR W1 -、-CONR W1 -、-NR W1 CO-, -C(=O)O- or -OC(=O)-, wherein one or more -CH2- in the alkylene group is optionally replaced by 1-4 groups selected from -O-, -S-, -NR W1 - or -CO-, the alkylene group is optionally further substituted by 1-4 groups selected from halogen, =O, C 1-4 Alkyl, halogenated C 1-4 Substitution with alkyl, CN, OH and NH2 substituents;

[0211] R W1 Selected from H, C 1-4 Alkyl, halogen;

[0212] and the peptide compound is optionally linked to a protecting group;

[0213] The protecting group is selected from Ac, glutaryl, succinyl, NH2 or OH;

[0214] Alternatively, the polypeptide is reacted with reactive groups Xa1, Xa6, Xa 10 Separated by covalent bonds formed with the molecular scaffold to form at least two polypeptide rings;

[0215] Provided that: the peptide compound is not selected from the following structure: (Ac)Pen-Asn-Thr-Trp(CH3)-Lys(Ac)-Pen-Phe[4-(2-aminoethoxy)]-[2-Nal]-Thp-Glu-Asn-[3-Pal]-Sarc(NH2), wherein a disulfide bond is formed between Pen and Pen.

[0216] Furthermore, the peptide compound has an amino acid sequence of formula (I):

[0217] Xa1-Xa2-Xa3-Xa4-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Xa 11 -Xa 12 -Xa 13 (I)

[0218] wherein Xa1 and Xa6 are each independently selected from Pen, Asn, Ala, Ala(3-amino), Ala(2-ethyne), Ala(3-azido), Ala(2-ethene), Val(2-ethene), Asp, 2,4-diaminobutyric acid, Ser, Cys, Hcys, and Glu, and the residues of Xa1 and Xa6 react to form a peptide ring;

[0219] Xa2 is selected from Asn, His, or analogs of Asn and His;

[0220] Xa3 is selected from Thr or an analog of Thr;

[0221] Xa4 is selected from Trp or an analog of Trp;

[0222] Xa5 is selected from Lys, Gln, Arg or an analog of Lys, Gln and Arg;

[0223] Xa7 is selected from Phe or an analog of Phe;

[0224] Xa8 is selected from Phe, Trp, 2-Nal or an analog of Phe, Trp and 2-Nal;

[0225] Xa9 is selected from Thp or an analog of Thp;

[0226] XA 10 Selected from Glu, Cys or analogs of Glu and Cys;

[0227] XA 11 selected from Asn, Lys, or analogs of Asn and Lys;

[0228] XA 12 selected from 3-Pal, Phe, Asp, or analogs of 3-Pal, Phe, and Asp;

[0229] XA 13 Selected from Sarc or an analog of Sarc;

[0230] Alternatively, Xa1, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa10 、Xa 11 、Xa 12 、Xa 13 Any amino acid residues in are linked through L1 to form one or more peptide rings;

[0231] L1 is selected from W1-R L -W2;

[0232] R L Selected from bond, C 1-6 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 6-10 membered aryl, wherein the alkylene, alkenylene, alkynylene, cycloalkyl, heterocycloalkyl, heteroaryl, aryl are optionally further substituted by 1-4 R L1 replace;

[0233] R L1 are independently selected from halogen, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 1-4 Alkoxy, 3-6 membered cycloalkyl, COOH, NH2, -NH-C(=O)-C 1-4 Alkyl, wherein the alkyl, alkoxy, and cycloalkyl groups are optionally further substituted with 1 to 4 substituents selected from halogen, CN, OH, and NH2;

[0234] W1 and W2 are each independently selected from a bond, C 1-6 Alkylene, -O-, -S-, -NR W1 -、-CONR W1 -、-NR W1 CO-, -C(=O)O- or -OC(=O)-, wherein one or more -CH2- in the alkylene group is optionally replaced by 1-4 groups selected from -O-, -S-, -NR W1 - or -CO-, the alkylene group is optionally further substituted by 1-4 groups selected from halogen, =O, C 1-4 Alkyl, halogenated C 1-4 Substitution with alkyl, CN, OH and NH2 substituents;

[0235] R W1 Selected from H, C 1-4 Alkyl, halogen;

[0236] and the peptide compound is optionally linked to a protecting group;

[0237] The protecting group is selected from Ac, glutaryl, succinyl, NH2 or OH;

[0238] Provided that: the peptide compound is not selected from the following structure: (Ac)Pen-Asn-Thr-Trp(CH3)-Lys(Ac)-Pen-Phe[4-(2-aminoethoxy)]-[2-Nal]-Thp-Glu-Asn-[3-Pal]-Sarc(NH2), wherein a disulfide bond is formed between Pen and Pen.

[0239] Furthermore, the peptide compound has an amino acid sequence of formula (I):

[0240] Xa1-Xa2-Xa3-Xa4-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Xa 11 -Xa 12 -Xa 13 (I)

[0241] wherein Xa1 and Xa6 are each independently selected from Pen, Asn, Ala, Ala(3-amino), Ala(2-ethyne), Ala(3-azido), Ala(2-ethene), and Val(2-ethene), and the residues of Xa1 and Xa6 react to form a peptide ring;

[0242] Xa2 is selected from Asn, His, or analogs of Asn and His;

[0243] Xa3 is selected from Thr or an analog of Thr;

[0244] Xa4 is selected from Trp or an analog of Trp;

[0245] Xa5 is selected from Lys or an analog of Lys;

[0246] Xa7 is selected from Phe or an analog of Phe;

[0247] Xa8 is selected from Phe, Trp, 2-Nal or an analog of Phe, Trp and 2-Nal;

[0248] Xa9 is selected from Thp or an analog of Thp;

[0249] XA 10 Selected from Glu or Glu analogs;

[0250] XA 11 selected from Asn, Lys, or analogs of Asn and Lys;

[0251] XA 12 selected from 3-Pal, Phe, Asp, or analogs of 3-Pal, Phe, and Asp;

[0252] XA 13 Selected from Sarc or an analog of Sarc;

[0253] Alternatively, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa 10 、Xa 11 、Xa 12 、Xa 13 Any amino acid residues in are linked through L1 to form a peptide ring;

[0254] L1 is selected from W1-R L -W2;

[0255] R L Selected from bond, C 1-6 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 6-10 membered aryl, wherein the alkylene, alkenylene, alkynylene, cycloalkyl, heterocycloalkyl, heteroaryl, aryl are optionally further substituted by 1-4 R L1 replace;

[0256] R L1 are independently selected from halogen, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 1-4 Alkoxy, 3-6 membered cycloalkyl, COOH, NH2, wherein the alkyl, alkoxy, and cycloalkyl groups are optionally further substituted with 1-4 substituents selected from halogen, CN, OH, and NH2;

[0257] W1 and W2 are each independently selected from a bond, C 1-6 Alkylene, -O-, -S-, -NR W1 -、-CONR W1 -、-NR W1 CO-, -C(=O)O- or -OC(=O)-, wherein one or more -CH2- in the alkylene group is optionally replaced by 1-4 groups selected from -O-, -S-, -NR W1 - or -CO-, the alkylene group is optionally further substituted by 1-4 groups selected from halogen, =O, C 1-4 Alkyl, halogenated C 1-4 Substitution with alkyl, CN, OH and NH2 substituents;

[0258] R W1 Selected from H, C 1-4 Alkyl, halogen;

[0259] and the peptide compound is optionally linked to a protecting group;

[0260] The protecting group is selected from Ac, glutaryl, succinyl, NH2 or OH;

[0261] Provided that: the peptide compound is not selected from the following structure: (Ac)Pen-Asn-Thr-Trp(CH3)-Lys(Ac)-Pen-Phe[4-(2-aminoethoxy)]-[2-Nal]-Thp-Glu-Asn-[3-Pal]-Sarc(NH2), wherein a disulfide bond is formed between Pen and Pen.

[0262] As a more specific second technical solution of the present invention, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the peptide compound has an amino acid sequence of formula (II) or formula (II-1):

[0263] (Ac)Xa1-Xa2-Thr-Xa4-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Asn-(3-Pal)-Sarc(NH2) (II)

[0264] (Ac)Xa1-Xa2-Thr-Xa4-Lys(Ac)-Xa6-Xa7-Xa8-Xa9-Glu-Asn-(3-Pal)-Sarc(NH2) (II-1)

[0265] The residues of Xa1 and Xa6 react to form a peptide ring; or the residues of Xa1 and Xa6 are linked by L1 to form a peptide ring;

[0266] The definitions of other groups are consistent with those of any of the above technical solutions.

[0267] Furthermore, the peptide compound has an amino acid sequence of formula (II-1):

[0268] (Ac)Xa1-Xa2-Thr-Xa4-Lys(Ac)-Xa6-Xa7-Xa8-Xa9-Glu-Asn-(3-Pal)-Sarc(NH2) (II-1)

[0269] Among them, the residues of Xa1 and Xa6 react to form a peptide ring;

[0270] The definitions of other groups are consistent with those of any of the above technical solutions.

[0271] As a more specific third technical solution of the present invention, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the peptide compound has an amino acid sequence of formula (III) or formula (III-1):

[0272] (Ac)Xa1-Xa2-Thr-Trp(R1)-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Asn-(3-Pal)-Sarc(NH2) (III)

[0273] (Ac)Xa1-Xa2-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-Xa8-Xa9-Glu-Asn-(3-Pal)-Sarc(NH2) (III-1)

[0274] The residues of Xa1 and Xa6 react to form a peptide ring; or the residues of Xa1 and Xa6 are linked by L1 to form a peptide ring;

[0275] The residues of Trp (R1) and Xa5 are directly condensed or linked via L1 to form a peptide ring;

[0276] Or the residues of Trp (CH3) and Lys (Ac) are directly condensed or linked through L1 to form a peptide ring;

[0277] or Xa1, Xa6, Xa 10 Forming a bicyclic peptide with the molecular scaffold;

[0278] R1 is selected from H, C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-8 membered heterocycloalkyl, said alkyl, cycloalkyl, heterocycloalkyl optionally further substituted by 1-4 groups selected from halogen, =O, C 1-4 Alkyl, halogenated C 1-4 Substitution with alkyl, CN, OH and NH2 substituents;

[0279] Furthermore, the peptide compound has an amino acid sequence of formula (III) or formula (III-1):

[0280] (Ac)Xa1-Xa2-Thr-Trp(R1)-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Asn-(3-Pal)-Sarc(NH2) (III)

[0281] (Ac)Xa1-Xa2-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-Xa8-Xa9-Glu-Asn-(3-Pal)-Sarc(NH2) (III-1)

[0282] Among them, the residues of Xa1 and Xa6 react to form a peptide ring;

[0283] And the residues of Trp (R1) and Xa5 are linked by L1 to form a peptide ring;

[0284] Or the residues of Trp (CH3) and Lys (Ac) are linked through L1 to form a peptide ring;

[0285] or Xa1, Xa6, Xa 10 Forming a bicyclic peptide with the molecular scaffold;

[0286] R1 is selected from H, C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-8 membered heterocycloalkyl, said alkyl, cycloalkyl, heterocycloalkyl optionally further substituted by 1-4 groups selected from halogen, =O, C 1-4 Alkyl, halogenated C 1-4 Substitution with alkyl, CN, OH and NH2 substituents;

[0287] The definitions of other groups are consistent with those of any of the above technical solutions.

[0288] Furthermore, the peptide compound has an amino acid sequence of formula (III-1):

[0289] (Ac)Xa1-Xa2-Thr-Trp(R1)-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Asa-(3-Pal)-Sarc(NH2) (III)

[0290] (Ac)Xa1-Xa2-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-Xa8-Xa9-Glu-Asn-(3-Pal)-Sarc(NH2) (III-1)

[0291] Among them, the residues of Xa1 and Xa6 react to form a peptide ring;

[0292] And the residues of Trp (R1) and Xa5 are linked by L1 to form a peptide ring;

[0293] Or the residues of Trp (CH3) and Lys (Ac) are linked through L1 to form a peptide ring;

[0294] R1 is selected from H, C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-8 membered heterocycloalkyl, said alkyl, cycloalkyl, heterocycloalkyl optionally further substituted by 1-4 groups selected from halogen, =O, C 1-4 Alkyl, halogenated C 1-4 Substitution with alkyl, CN, OH and NH2 substituents;

[0295] The definitions of other groups are consistent with those of any of the above technical solutions.

[0296] Furthermore, the peptide compound has an amino acid sequence of formula (III-1):

[0297] (Ac)Xa1-Xa2-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-Xa8-Xa9-Glu-Asn-(3-Pal)-Sarc(NH2) (III-1)

[0298] Among them, the residues of Xa1 and Xa6 react to form a peptide ring;

[0299] And the residues of Trp (CH3) and Lys (Ac) are linked through L1 to form a peptide ring;

[0300] The definitions of other groups are consistent with those of any of the above technical solutions.

[0301] As a more specific fourth technical solution of the present invention, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the peptide compound has an amino acid sequence of formula (IV), formula (IV-1) or formula (V):

[0302] (N-terminal)Xa1-Asn-Thr-Trp(R1)-Xa5-Xa6-Xa7-(2-Nal)-Xa9-Xa 10 -Xa 11 -Xa 12 -Sarc(C-terminus) (IV)

[0303] (N-terminal)Xa1-Asn-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-(2-Nal)-Xa9-Glu-Xa 11 -Xa 12 -Sarc(C-terminus) (IV-1)

[0304] or (N-terminal) Xa1-His-Thr-Trp(R1)-Xa5-Xa6-Xa7-(2-Nal)-Xa9-Xa 10 -Xa 11 -Xa 12 -Sarc(C-terminal) (V)

[0305] The residues of Xa1 and Xa6 react to form a peptide ring; or the residues of Xa1 and Xa6 are linked by L1 to form a peptide ring;

[0306] the presence or absence of protecting groups at the N-terminus and C-terminus;

[0307] or N-terminal conjugated modifying group;

[0308] 2-Nal and Xa 12 The residues are linked by L1 to form a peptide loop; and / or

[0309] Xa9 and Xa 12 The residues are linked by L1 to form a peptide loop; and / or

[0310] Lys(Ac) and Xa7 residues are linked via L1 to form a peptide ring; and / or

[0311] Xa7 vs. Xa 11 The residues are linked by L1 to form a peptide loop; and / or

[0312] The residues of 2-Nal and Glu are linked via L1 to form a peptide ring; and / or

[0313] The residues Xa1 and Glu are linked via L1 to form a peptide ring; and / or

[0314] Xa1 and Xa 11 The residues are linked by L1 to form a peptide loop; and / or

[0315] Xa1 and Xa 10 The residues are linked by L1 to form a peptide loop; and / or

[0316] The residues of 2-Nal and Sarc are linked to form a peptide ring via L1; and / or

[0317] Xa9 and Sarc residues are linked via L1 to form a peptide loop; and / or

[0318] XA 11 The residues of Sarc are linked via L1 to form a peptide loop; and / or

[0319] The residues of Xa1, Sarc and Glu are linked via L1 to form a peptide ring; and / or

[0320] or Xa1, Xa6, Xa 10 Forming a bicyclic peptide with the molecular scaffold;

[0321] R1 is selected from C 1-2 Alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally further substituted with 1-4 substituents selected from F, Cl, Br, =O, methyl, ethyl, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2F, -CHF2, -CF3, CN, OH and NH2;

[0322] The conditions are: (1) when the N-terminal Xa1 is linked to other amino acid residues via L1, the N-terminal protecting group does not exist;

[0323] (2) When the C-terminal Sarc is linked to other amino acid residues via L1, the C-terminal protecting group does not exist;

[0324] The definitions of other groups are consistent with those of any of the above technical solutions.

[0325] Furthermore, the peptide compound has an amino acid sequence of formula (IV) or formula (IV-1):

[0326] (N-terminal)Xa1-Asn-Thr-Trp(R1)-Xa5-Xa6-Xa7-(2-Nal)-Xa9-Xa 10 -Xa 11 -Xa 12 -Sarc(C-terminus) (IV)

[0327] (N-terminal)Xa1-Asn-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-(2-Nal)-Xa9-Glu-Xa 11 -Xa 12 -Sarc (C-terminus) (IV-1) wherein the residues Xa1 and Xa6 react to form a peptide ring;

[0328] The presence or absence of protecting groups at the N-terminus and C-terminus; 2-Nal and Xa 12 The residues are linked by L1 to form a peptide loop; and / or

[0329] Xa9 and Xa 12 The residues are linked by L1 to form a peptide loop; and / or

[0330] Lys(Ac) and Xa7 residues are linked via L1 to form a peptide ring; and / or

[0331] Xa7 vs. Xa 11 The residues are linked by L1 to form a peptide loop; and / or

[0332] The residues of 2-Nal and Glu are linked via L1 to form a peptide ring; and / or

[0333] The residues Xa1 and Glu are linked via L1 to form a peptide ring; and / or

[0334] Xa1 and Xa 11 The residues are linked by L1 to form a peptide loop; and / or

[0335] Xa1 and Xa10 The residues are linked by L1 to form a peptide loop; and / or

[0336] The residues of 2-Nal and Sarc are linked to form a peptide ring via L1; and / or

[0337] Xa9 and Sarc residues are linked via L1 to form a peptide loop; and / or

[0338] XA 11 The residues of Sarc are linked via L1 to form a peptide loop; and / or

[0339] The residues of Xa1, Sarc, and Glu are linked by L1 to form a peptide ring;

[0340] R1 is selected from C 1-2 Alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally further substituted with 1-4 substituents selected from F, Cl, Br, =O, methyl, ethyl, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2F, -CHF2, -CF3, CN, OH and NH2;

[0341] The conditions are: (1) when the N-terminal Xa1 is linked to other amino acid residues via L1, the N-terminal protecting group does not exist;

[0342] (2) When the C-terminal Sarc is linked to other amino acid residues via L1, the C-terminal protecting group does not exist;

[0343] The definitions of other groups are consistent with those of any of the above technical solutions.

[0344] Furthermore, the peptide compound has an amino acid sequence of formula (IV-1):

[0345] (N-terminal)Xa1-Asn-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-(2-Nal)-Xa9-Glu-Xa 11 -Xa 12 -Sarc(C-terminus) (IV-1)

[0346] Among them, the residues of Xa1 and Xa6 react to form a peptide ring;

[0347] the presence or absence of protecting groups at the N-terminus and C-terminus;

[0348] 2-Nal and Xa 12 The residues are linked by L1 to form a peptide loop; and / or

[0349] Xa9 and Xa12 The residues are linked by L1 to form a peptide loop; and / or

[0350] Lys(Ac) and Xa7 residues are linked via L1 to form a peptide ring; and / or

[0351] Xa7 vs. Xa 11 The residues are linked by L1 to form a peptide loop; and / or

[0352] The residues of 2-Nal and Glu are linked via L1 to form a peptide ring; and / or

[0353] The residues Xa1 and Glu are linked via L1 to form a peptide ring; and / or

[0354] Xa1 and Xa 11 The residues are linked by L1 to form a peptide loop; and / or

[0355] The residues of 2-Nal and Sarc are linked to form a peptide ring via L1; and / or

[0356] Xa9 and Sarc residues are linked via L1 to form a peptide loop; and / or

[0357] XA 11 The residues of Sarc are linked via L1 to form a peptide loop; and / or

[0358] The residues of Xa1, Sarc, and Glu are linked by L1 to form a peptide ring;

[0359] The conditions are: (1) when the N-terminal Xa1 is linked to other amino acid residues via L1, the N-terminal protecting group does not exist;

[0360] (2) When the C-terminal Sarc is linked to other amino acid residues via L1, the C-terminal protecting group does not exist;

[0361] The definitions of other groups are consistent with those of any of the above technical solutions. As a more specific fifth technical solution of the present invention, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein

[0362] The residues of Xa1 and Xa6 react to form a peptide ring or form a cyclic peptide through L1, and Xa4 and Xa5, Xa1 and Xa 10 , Xa8 and Xa 10 , Xa8 and Xa 12 , Xa8 and Xa 13 , Xa9 and Xa 13 , Xa5 and Xa7, Xa 11 With Xa 13, Xa1 and Xa 11 , Xa7 and Xa 11 One or two groups of residues in the peptide are directly condensed or linked through L1 to form a peptide ring;

[0363] or Xa1, Xa6, Xa 10 Forming a bicyclic peptide with the molecular scaffold;

[0364] The definitions of other groups are consistent with those of any of the above technical solutions.

[0365] Furthermore, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the residues of Xa1 and Xa6 react to form a peptide ring, and Xa4 and Xa5, Xa1 and Xa 10 , Xa8 and Xa 10 , Xa8 and Xa 12 , Xa8 and Xa 13 , Xa9 and Xa 13 , Xa5 and Xa7, Xa 11 With Xa 13 , Xa1 and Xa 11 , Xa7 and Xa 11 One or two groups of residues in the peptide are directly condensed or linked through L1 to form a peptide ring;

[0366] or Xa1, Xa6, Xa 10 Forming a bicyclic peptide with the molecular scaffold;

[0367] The definitions of other groups are consistent with those of any of the above technical solutions.

[0368] As a more specific sixth technical solution of the present invention, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the peptide compound and the amino acid residues in the peptide compound are connected through a polyethylene glycol chain to form a dimer compound; the polyethylene glycol chain is

[0369] n is any integer selected from 0-99;

[0370] The definitions of other groups are consistent with those of any of the above technical solutions. As a more specific seventh technical solution of the present invention, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the modifying group is p is selected from any integer between 0 and 50, q is selected from any integer between 0 and 50; in some embodiments, the modifying group is p is selected from any integer between 0 and 50, q is selected from any integer between 0 and 50;

[0371] The definitions of other groups are consistent with those of any of the above technical solutions.

[0372] Further, wherein the modifying group is p is selected from any integer between 0 and 5, and q is selected from any integer between 0 and 5;

[0373] The definitions of other groups are consistent with those of any of the above technical solutions.

[0374] Further, wherein the modifying group is

[0375] The definitions of other groups are consistent with those of any of the above technical solutions.

[0376] As a more specific eighth technical solution of the present invention, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein

[0377] The residues Xa1 and Xa6 react to form the following structure:

[0378] wherein the * end is the Xa1 end, Xa1 and Xa2 are connected through the * position, and the NH2 end is connected to a protecting group; or the * end is the Xa1 end, Xa1 and Xa2 are connected through the * position, and the NH2 end is connected to a protecting group or the NH2 end is conjugated to a modifying group;

[0379] Xa2 is selected from Asn, His, or an analog of His selected from Or the His analogue is selected from Or the His analogue is selected from

[0380] Xa3 is selected from Thr;

[0381] Xa4 is selected from the group consisting of analogs of Trp selected from the group consisting of

[0382] Xa5 is selected from Lys, Gln, Arg, Cit, or an analog of Arg or Lys, wherein the analog of Arg or Lys is selected from

[0383] Alternatively, the Xa5 residue is conjugated to a modifying group;

[0384] Xa7 is selected from Phe or a Phe analog selected from

[0385] Alternatively, the Xa7 residue is conjugated to a modifying group;

[0386] Xa8 is selected from Phe, Trp, 2-Nal, or analogs of Phe, Trp and 2-Nal; the analogs of Phe, Trp and 2-Nal are selected from Or choose

[0387] Xa9 is selected from Thp or an analog of Thp selected from

[0388] XA 10 Selected from Glu or Cys;

[0389] XA 11 Selected from Asn or Lys;

[0390] XA 12 Selected from 3-Pal or Phe;

[0391] The molecular framework is selected from: Or choose

[0392] The definitions of other groups are consistent with those of any of the above technical solutions.

[0393] Furthermore, the peptide compound, its stereoisomer, or its pharmaceutically acceptable salt, solvate, or dimer, wherein the residues Xa1 and Xa6 react to form the following structure:

[0394] The * end is the Xa1 end, Xa1 and Xa2 are connected through the * position, and the NH2 end is connected to the protecting group;

[0395] Xa2 is selected from Asn, His or an analog of His, wherein the analog of His is selected from

[0396] Xa4 is selected from the group consisting of analogs of Trp selected from the group consisting of

[0397] Xa5 is selected from Lys, Gln, Arg or an analog of Arg selected from

[0398] Xa7 is selected from Phe or a Phe analog selected from

[0399] Xa8 is selected from Phe, Trp, 2-Nal or analogs of Phe, Trp and 2-Nal; the analogs of Phe, Trp and 2-Nal are selected from

[0400] Xa9 is selected from Thp or an analog of Thp selected from

[0401] XA 10 Selected from Glu or Cys;

[0402] XA 11 Selected from Asn or Lys;

[0403] XA 12 Selected from 3-Pal or Phe;

[0404] The molecular framework is selected from:

[0405] The definitions of other groups are consistent with those of any of the above technical solutions.

[0406] Furthermore, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein

[0407] The residues Xa1 and Xa6 react to form the following structure: Alternatively, the residues Xa1 and Xa6 react to form the following structure: Alternatively, the residues Xa1 and Xa6 react to form the following structure:

[0408] The * end is the Xa1 end, Xa1 and Xa2 are connected through the * position, and the NH2 end is connected to the protecting group;

[0409] Xa2 is selected from Asn, His or an analog of His, wherein the analog of His is selected from

[0410] Xa4 is selected from the group consisting of analogs of Trp selected from the group consisting of

[0411] Xa5 is selected from Lys, Gln, Arg or an analog of Arg selected from

[0412] Xa7 is selected from Phe or a Phe analog selected from In some embodiments, Xa7 is selected from Phe or an analog of Phe selected from

[0413] Xa8 is selected from Phe, Trp, 2-Nal or analogs of Phe, Trp and 2-Nal; the analogs of Phe, Trp and 2-Nal are selected from Or the Trp analogue is selected from

[0414] Xa9 is selected from Thp or an analog of Thp selected from

[0415] XA 10 Selected from Glu or Cys;

[0416] XA 11 Selected from Asn or Lys;

[0417] XA 12 Selected from 3-Pal or Phe;

[0418] The definitions of other groups are consistent with those of any of the above technical solutions.

[0419] As a more specific ninth technical solution of the present invention, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the molecular framework is selected from: In some embodiments, the molecular scaffold is selected from:

[0420] The definitions of other groups are consistent with those of any of the above technical solutions.

[0421] As a more specific tenth technical solution of the present invention, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein

[0422] L1 is selected from the group consisting of a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2)r -NH-, -C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -、-C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-, C 1-6 Alkylene, -C(=O)-, -C(=O)-(CH2) r -NH-, -(CH2) r -O-(CH2) r -NH-, -O-(CH2) r -O-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-, -(CH2) r -NH-C(=O)-(CH2) r -、-C(=O)-(CH2)-(OCH2CH2) a -NH-;

[0423] Further, L1 is selected from a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2)r -O-(CH2) r -、-C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-, C 1-2 Alkylene, -C(=O)-, -C(=O)-(CH2) r -NH-, -(CH2) r -O-(CH2) r -NH-, -O-(CH2) r -O-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-;

[0424] Further, L1 is selected from a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -、-C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r-NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-, C 1-2 Alkylene, -C(=O)-, -C(=O)-(CH2) r -NH-, or selected from -(CH2) r -O-(CH2) r -NH-, -O-(CH2) r -O-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -(CH2) r -NH-;

[0425] Furthermore, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein L1 is selected from a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -、-C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r-、-O-(CH2) r -NH-, C 1-2 Alkylene, -C(=O)-(CH2) r -NH-, Or L1 is selected from

[0426] r is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0427] a is selected from 3, 4, 5 or 6;

[0428] The definitions of other groups are consistent with those of any of the above technical solutions.

[0429] As a more specific eleventh technical solution of the present invention, the peptide compound, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the peptide compound is selected from one of the structures in the following Table 1:

[0430] Table 1:

[0431] The present invention also relates to a pharmaceutical composition comprising the peptide compound or a pharmaceutically acceptable salt thereof according to any one of the first to eleventh technical solutions, and a pharmaceutically acceptable carrier and / or excipient.

[0432] The present invention also relates to a use of the peptide compound or pharmaceutically acceptable salt thereof, or the pharmaceutical composition, described in any one of the first to eleventh technical solutions, in the preparation of a drug for preventing and treating a disease or condition in which IL-23 is overexpressed in a diseased tissue of a subject.

[0433] Furthermore, the diseases or conditions that overexpress IL-23 include inflammatory bowel disease, Crohn's disease and psoriasis.

[0434] The present invention also relates to a pharmaceutical composition or pharmaceutical preparation, comprising 1-1500 mg of the peptide compound or a pharmaceutically acceptable salt thereof described in any one of the first to eleventh technical solutions above, and a pharmaceutically acceptable carrier and / or excipient.

[0435] The present invention also relates to a method for treating a disease in a mammal or a human, comprising administering to a subject a therapeutically effective amount of a peptide compound or a pharmaceutically acceptable salt thereof according to any one of the first to eleventh technical solutions, wherein the therapeutically effective amount is preferably 1-1500 mg, and the disease is preferably inflammatory bowel disease, Crohn's disease and psoriasis.

[0436] The present invention also provides a composition or pharmaceutical preparation comprising the peptide compound or pharmaceutically acceptable salt thereof according to any of the aforementioned embodiments, and a pharmaceutically acceptable carrier and / or excipient. The pharmaceutical composition may be in the form of a unit dosage form (a unit dosage form is also referred to as a "dose strength").

[0437] Furthermore, the composition or pharmaceutical preparation of the present invention contains 1-1500 mg of the peptide compound or a pharmaceutically acceptable salt thereof according to any one of the aforementioned schemes, and a pharmaceutically acceptable carrier and / or excipient.

[0438] The present invention also provides the use of the peptide compound described in any of the aforementioned embodiments, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for preventing or treating a disease or condition caused by overexpression of IL-23 in a diseased tissue of a subject. Furthermore, the disease or condition caused by overexpression of IL-23 includes inflammatory bowel disease, Crohn's disease, and psoriasis.

[0439] The present invention also provides a method for treating a disease in a mammal or human, comprising administering to a subject a therapeutically effective amount of a peptide compound or a pharmaceutically acceptable salt thereof as described in any of the aforementioned embodiments, wherein the disease is preferably inflammatory bowel disease, Crohn's disease, and psoriasis, and the therapeutically effective amount is preferably 1-1500 mg. In some embodiments, the mammal described in the present invention does not include humans.

[0440] As used herein, an "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a compound disclosed herein to provide a sufficient amount of relief to some extent from one or more symptoms of the disease or condition being treated. In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of the disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a peptide compound disclosed herein or a pharmaceutically acceptable salt thereof required to provide a clinically significant reduction in disease symptoms. Examples of therapeutically effective amounts include, but are not limited to, 1-1500 mg, 1-1400 mg, 1-1300 mg, 1-1200 mg, 1-1000 mg, 1-900 mg, 1-800 mg, 1-700 mg, 1-600 mg, 1-500 mg, 1-400 mg, 1-300 mg, 1-250 mg, 1-200 mg, 1-150 mg, 1-125 mg, 1-100 mg, 1-80 mg, 1-60 mg, 1-50 mg, 1-40 mg, 1-25 mg, 1- 20mg, 5-1500mg, 5-1000mg, 5-900mg, 5-800mg, 5-700mg, 5-600mg, 5-500mg, 5-400mg, 5-300mg, 5-250mg, 5-200mg, 5 -150mg, 5-125mg, 5-100mg, 5-90mg, 5-70mg, 5-80mg, 5-60mg, 5-50mg, 5-40mg, 5-30mg, 5-25mg, 5-20mg, 10-1500mg, 10-1000mg, 10-900mg, 10-800mg, 10-700mg, 10-600mg, 10-500mg, 10-450mg, 10-400mg, 10-300mg, 10-250mg, 10-20 0mg, 10-150mg, 10-125mg, 10-100mg, 10-90mg, 10-80mg, 10-70mg, 10-60mg, 10-50mg, 10-40mg, 10-30mg, 10-20mg; 2 0-1500mg, 20-1000mg, 20-900mg, 20-800mg, 20-700mg, 20-600mg, 20-500mg, 20-400mg, 20-350mg, 20-300mg, 20-25 0mg, 20-200mg, 20-150mg, 20-125mg, 20-100mg, 20-90mg, 20-80mg, 20-70mg, 20-60mg, 20-50mg, 20-40mg, 20-30mg;50-1500mg, 50-1000mg, 50-900mg, 50-800mg, 50-700mg, 50-600mg, 50-500mg, 50-400mg, 50-300mg, 50-250mg, 50-200mg, 50-150mg, 50-125mg, 5 0-100mg; 100-1500mg, 100-1000mg, 100-900mg, 100-800mg, 100-700mg, 100-600mg, 100-500mg, 100-400mg, 100-300mg, 100-250mg, 100-200mg;

[0441] In some embodiments, the pharmaceutical composition or formulation of the present invention contains the above-mentioned therapeutically effective amount of the peptide compound of the present invention or a pharmaceutically acceptable salt thereof;

[0442] The present invention relates to a pharmaceutical composition or pharmaceutical preparation, comprising a therapeutically effective amount of a peptide compound of the present invention or a pharmaceutically acceptable salt thereof and a carrier and / or excipient. The pharmaceutical composition may be in the form of a unit preparation (the amount of the main drug in the unit preparation is also referred to as a "preparation specification"). In some embodiments, the pharmaceutical composition includes but is not limited to 1 mg, 1.25 mg, 2.5 mg, 5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 460 mg, 470 mg, 480 mg, 490 mg, 500 mg, 510 mg, 520 mg, 530 mg, 540 mg, 550 mg, 560 mg, 570 mg, 580 mg, 0 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, 1500 mg of a peptide compound of the present invention or a pharmaceutically acceptable salt thereof.

[0443] A method for treating a disease in a mammal or human, comprising administering to a subject a therapeutically effective amount of a peptide compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and / or excipient, wherein the therapeutically effective amount is preferably 1-1500 mg, and the disease is preferably inflammatory bowel disease, Crohn's disease, and psoriasis.

[0444] A method for treating a disease in a mammal or a human, comprising administering a peptide compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and / or excipient to a subject at a daily dose of 1-1500 mg / day, wherein the daily dose can be a single dose or divided doses. In some embodiments, the daily dose includes but is not limited to 10-1500 mg / day, 20-1500 mg / day, 25-1500 mg / day, 50-1500 mg / day, 75-1500 mg / day, 100-1500 mg / day, 200-1500 mg / day, 10-1000 mg / day, 20-1000 mg / day, 25-1000 mg / day, 50-1000 mg / day, 75-1000 mg / day, 100-1000 mg / day, g / day, 200-1000 mg / day, 25-800 mg / day, 50-800 mg / day, 100-800 mg / day, 200-800 mg / day, 25-400 mg / day, 50-400 mg / day, 100-400 mg / day, 200-400 mg / day, in some embodiments, daily doses include but are not limited to 1 mg / day, 5 mg / day, 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 75 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 200 mg / day, 300 mg / day, 400 mg / day, 600 mg / day, 800 mg / day, 1000 mg / day, 1200 mg / day, 1400 mg / day, 1500 mg / day.

[0445] The present invention relates to a kit which may include a composition in single-dose or multi-dose form, wherein the kit contains a peptide compound of the present invention or a pharmaceutically acceptable salt thereof, and the amount of the compound of the present invention or its stereoisomer or pharmaceutically acceptable salt is the same as that in the above-mentioned pharmaceutical composition.

[0446] The amount of the compound of the invention or its stereoisomer or pharmaceutically acceptable salt in the present invention is in each case calculated as the free base.

[0447] "Preparation specifications" refers to the weight of the main drug contained in each vial, tablet or other unit preparation.

[0448] the term

[0449] Unless otherwise specified in the present invention, the terms of the present invention have the following meanings:

[0450] As used herein, "peptide" refers broadly to a sequence of two or more amino acids linked together by peptide bonds. It should be understood that this term does not imply a specific length of amino acid polymer, nor is it intended to imply or distinguish whether a polypeptide is produced using recombinant technology, chemical synthesis or enzymatic synthesis, or whether it is naturally occurring.

[0451] The carbon, hydrogen, oxygen, sulfur, nitrogen or halogen involved in the groups and compounds of the present invention include their isotopes, and the carbon, hydrogen, oxygen, sulfur, nitrogen or halogen involved in the groups and compounds of the present invention are optionally further replaced by one or more of their corresponding isotopes, wherein the isotopes of carbon include 12 C. 13 C and 14 C, hydrogen isotopes include protium (H), deuterium (deuterium, also known as heavy hydrogen), tritium (T, also known as super tritium), oxygen isotopes include 16 O. 17 O and 18 O, sulfur isotopes include 32 S. 33 S. 34 S and 36 S, nitrogen isotopes include 14 N and 15 N, an isotope of fluorine 19 F, chlorine isotopes include 35 Cl and 37 Isotopes of Cl, bromine include 79 Br and 81 Br. Radiolabeled versions of the compounds disclosed herein can be prepared using standard methods known in the art.

[0452] "Dimer" of the present invention refers broadly to a peptide comprising two or more monomeric subunits. Certain dimers comprise two DRPs. Dimers of the present invention include homodimers and heterodimers. The monomeric subunits of the dimer can be connected at their C-terminal or N-terminal ends, or they can be connected via internal amino acid residues. Each monomeric subunit of the dimer can be connected by the same site, or each can be connected by different sites (e.g., C-terminal, N-terminal or internal sites).

[0453] The term "cyclization" or "peptide ring formation" as used herein refers to a reaction in which one part of a polypeptide molecule is linked to another part of the polypeptide molecule to form a closed ring, or one part of a polypeptide molecule is linked to several other parts of the polypeptide molecule to form multiple closed rings, such as by forming a disulfide bridge or other similar bonds, or by linker connection.

[0454] The "Ac" in the present invention refers to "acetyl";

[0455] As used herein, "derivatives" or "analogs" refer to products derived from the replacement of a hydrogen atom or atom group in a compound by another atom or atom group. It should be understood that amino acid analogs of peptide compounds as defined herein are within the scope of the present invention. Examples of such suitable modified amino acid derivatives include one or more modifications selected from the following: N-terminal and / or C-terminal modification; replacement of one or more amino acid residues with one or more non-natural amino acid residues (e.g., replacement of one or more polar amino acid residues with one or more isosteric or isoelectronic amino acids; replacement of one or more non-polar amino acid residues with other non-natural isosteric or isoelectronic amino acids); addition of a spacer group; replacement of one or more oxidation-sensitive amino acid residues with one or more oxidation-tolerant amino acid residues; replacement of one or more amino acid residues with alanine, replacement of one or more L-amino acid residues with one or more D-amino acid residues; N-alkylation of one or more amide bonds in a bicyclic peptide ligand; replacement of one or more amide bonds with surrogate bonds. bond); peptide backbone length modification; replacement or substitution of a hydrogen on the α-carbon of one or more amino acid residues with another chemical group; modification of amino acids such as glycine, alanine, phenylalanine, cysteine, lysine, glutamic acid / aspartic acid and tyrosine with suitable amine, thiol, carboxylic acid and phenol reactive reagents to functionalize the amino acids; and introduction or substitution of amino acids to introduce orthogonal reactivity suitable for functionalization, for example, amino acids carrying azide or alkyne groups allow functionalization with alkyne or azide carrying moieties, respectively.

[0456] Unless otherwise specified, all amino acids were used in the L-configuration.

[0457] Some common amino acid names and their three-letter and one-letter abbreviations are shown in the table below:

[0458] 2-Nal:

[0459] 3-Pal:

[0460] Thp:

[0461] Pen:

[0462] Pcn:

[0463] Ala(3-amino):

[0464] Ala(2-ethyne):

[0465] Ala(3-azido):

[0466] Ala(2-ethene):

[0467] Val(2-ethene):

[0468] 2,4-Diaminobutyric acid:

[0469] "Pharmaceutically acceptable salts" refer to salts of the compounds of the present invention that retain the biological effectiveness and properties of the free acids or free bases, and the free acids are reacted with non-toxic inorganic or organic bases, or the free bases are reacted with non-toxic inorganic or organic acids.

[0470] A "pharmaceutical composition" refers to a mixture of one or more compounds described herein, or stereoisomers, solvates, pharmaceutically acceptable salts or cocrystals thereof, with other ingredients, wherein the other ingredients include physiologically / pharmaceutically acceptable carriers and / or excipients.

[0471] "Carrier" refers to a system that does not cause significant irritation to the organism and does not eliminate the biological activity and properties of the administered compound, and can change the way the drug enters the human body and its distribution in the body, control the release rate of the drug and deliver the drug to the target organ. Non-limiting examples include microcapsules and microspheres, nanoparticles, liposomes, etc.

[0472] "Excipient" refers to a substance that is not itself a therapeutic agent and is used as a diluent, adjuvant, binder, and / or vehicle that is added to a pharmaceutical composition to improve its handling or storage properties or to allow or facilitate the formation of a compound or pharmaceutical composition into a unit dosage form for administration. As known to those skilled in the art, pharmaceutical excipients can provide various functions and can be described as wetting agents, buffers, suspending agents, lubricants, emulsifiers, disintegrants, absorbents, preservatives, surfactants, colorants, flavoring agents, and sweeteners. Examples of pharmaceutical excipients include, but are not limited to: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, and cross-linked carboxymethylcellulose (e.g., sodium cross-linked carboxymethylcellulose); (4) tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) pH buffer solutions; (21) polyesters, polycarbonates, and / or polyanhydrides; and (22) other nontoxic compatible substances used in pharmaceutical preparations. DETAILED DESCRIPTION

[0473] The present invention will be described in detail below through examples. Where specific conditions are not specified in the examples, the experimental methods are carried out according to conventional conditions. The examples are provided to better illustrate the present invention, but it should not be understood that the present invention is limited to the examples. Any non-essential improvements and adjustments made by those skilled in the art to the embodiments based on the above invention are still within the scope of protection of the present invention.

[0474] Detection method

[0475] The structures of the compounds were determined by mass spectrometry (MS).

[0476] MS was determined using (Agilent 6120B (ESI) and Agilent 6120B (APCI));

[0477] HPLC determination was performed using an Agilent 1260DAD high-pressure liquid chromatograph (Zorbax SB-C18 100 × 4.6 mm, 3.5 μM);

[0478] Brief description:

[0479] DCM: dichloromethane

[0480] DMF:N,N-dimethylformamide

[0481] DIEA: N,N-diisopropylethylamine

[0482] MeOH: methanol

[0483] TFA: trifluoroacetic acid

[0484] DMSO: dimethyl sulfoxide

[0485] DIC: N,N'-diisopropylcarbodiimide

[0486] HOBT: 1-Hydroxybenzotriazole

[0487] HOAT: N-Hydroxy-7-azabenzotriazole

[0488] Intermediate 1:

[0489] Step 1: Sodium nitrite (42.14 g, 610.7 mmol) was added to DMF (300 mL) and water (400 mL). After nitrogen replacement, hydrochloric acid (2 mol / L, 103 mL) was added dropwise at 0°C. Compound 1a (10 g, 76.3 mmol) was dissolved in DMF (300 mL) and added dropwise to the reaction solution within 2 h. The reaction was moved to room temperature and stirred overnight. The plate was detected to indicate that the starting material was completely consumed. Water (2 L) was added and extracted with ethyl acetate (500 mL x 3). The organic phases were combined and dried, and separated and purified by silica gel column chromatography (EA:PE = 5:1) to obtain compound 1b (7.4 g, 60.6%).

[0490] LC-MS (ESI): m / z = 161.0 [M+H] + .

[0491] Step 2: Compound 1b (7.4 g, 45.9 mmol) was dissolved in dichloromethane (100 mL), and triethylamine (7 g, 68.9 mmol) and di-tert-butyl dicarbonate (12 g, 55.2 mmol) were added. The reaction was stirred overnight, then diluted with dichloromethane (100 mL), washed three times with water (100 mL), and the organic phase was concentrated to obtain compound 1c (10 g, 83.2%).

[0492] LC-MS (ESI): m / z = 261.0 [M+H] + .

[0493] Step 3: Dissolve (±)benzyloxycarbonyl-a-phosphonoglycine trimethyl ester (14 g, 42.3 mmol) in dichloromethane (100 mL). After nitrogen substitution, add DBU (6.43 g, 42.3 mmol) and stir for 30 min. Then, add compound 1c (10 g, 38.4 mmol) dissolved in dichloromethane (100 mL) dropwise to the reaction mixture. Stir overnight. The reaction mixture is diluted with dichloromethane (100 mL) and washed with 5% aqueous citric acid (100 mL) and saturated brine (100 mL). Then, dry over anhydrous sodium sulfate, filter, and spin-dry. Purify by silica gel column chromatography (EA:PE = 3:1) to afford compound 1d (12 g, 67.1%).

[0494] LC-MS (ESI): m / z = 466.2 [M+H] + .

[0495] Step 4: Compound 1d (5 g, 10.74 mmol) was dissolved in a mixed solution of methanol (50 mL) and dichloromethane (20 mL), and (+)-1,2-bis(2S,5S)-2,5-diethylcyclobutanephosphanebenzene(cyclooctadiene)trifluoromethanesulfonate rhodium (0.5 g, 0.69 mmol) was added. The autoclave was filled with hydrogen to a pressure of about 4.0 bar, stirred at room temperature for 3 h, the solid was filtered out, and the reaction solution was concentrated to obtain compound 1e (5 g, 99.8%).

[0496] LC-MS (ESI): m / z = 468.2 [M+H] + .

[0497] Step 5: Compound 1e (5 g, 10.69 mmol) was dissolved in a mixed solution of methanol (50 mL) and dichloromethane (20 mL). Palladium on carbon (10%, 1 g) was added and stirred overnight under a hydrogen atmosphere. The solid was then filtered off and the reaction solution was dried to give compound 1f (3.2 g, 89.7%).

[0498] LC-MS (ESI): m / z = 334.2 [M+H] + .

[0499] Step 6: Compound 1f (3.2 g, 9.60 mmol) was added to dichloromethane (30 mL), and trifluoroacetic acid (10 mL) was added dropwise. The reaction was stirred at room temperature for 2 h. LCMS monitoring showed that the starting material was completely consumed. The crude product of compound 1g was directly dried and used in the next step without purification.

[0500] LC-MS (ESI): m / z = 234.1 [M+H] + .

[0501] Step 7: Compound 1g (2.2 g, 9.43 mmol) was dissolved in tetrahydrofuran (20 mL), and lithium hydroxide monohydrate (1.58 g, 37.7 mmol) and water (20 mL) were added. The reaction was stirred at room temperature overnight, and impurities were extracted with ethyl acetate (10 mL x 3). The pH of the aqueous phase was then adjusted to neutral with dilute hydrochloric acid (1N). The product precipitated, filtered, and dried to obtain compound 1h (2 g, 96.7%).

[0502] LC-MS (ESI): m / z = 220.1 [M+H] + .

[0503] Step 8: Compound 1h (2 g, 9.12 mmol) was dissolved in a mixed solution of acetonitrile (20 mL) and water (20 mL), and sodium bicarbonate (3.83 g, 45.6 mmol) and 9-fluorenylmethyl-N-succinimidyl carbonate (4.6 g, 13.7 mmol) were added. The reaction was stirred at room temperature overnight. After completion of the reaction, dilute hydrochloric acid was added dropwise to adjust the pH to neutral. The mixture was concentrated in vacuo at 40°C to remove most of the acetonitrile, and the solid was collected by filtration to obtain the crude product, which was separated and purified by silica gel column chromatography (DCM:MeOH=10:1) to obtain intermediate 1 (2.5 g, 62.1%).

[0504] LC-MS (ESI): m / z = 442.2 [M+H] + .

[0505] 1 H NMR(400MHz,DMSO-d6)δ12.81(s,1H),7.87(d,2H),7.68–7.57(m,3H),7.54–7.43(m,1H),7.42–7.35(m,2H),7.32– 7.22(m,2H),7.06(d,1H),6.99–6.90(m,1H),4.44–4.34(m,1H),4.21–3.93(m,3H),3.43–3.25(m,2H),2.47(s,3H).

[0506] Intermediate 2:

[0507] Step 1: Dissolve compound 2a (10.0 g, 75.65 mmol) in dichloromethane (100 mL). Add SnCl4 (23.7 g, 90.78 mmol) dropwise to the reaction mixture, and cool to 0°C. After 5 minutes, add 1,1-dichlorodimethyl ether (9.6 g, 83.22 mmol) dropwise, and stir at 0°C for 3 hours. After the reaction, add 200 mL of water to the reaction system. The resulting solution is extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The product is purified by column chromatography (EA:PE = 1:50) to afford compound 2b (4.1 g, 33.8%).

[0508] LC-MS (ESI): m / z = 161.1 [M+H] + .

[0509] Step 2: (±)benzyloxycarbonyl-a-phosphonoglycine trimethyl ester (9.9 g, 29.93 mmol) was dissolved in dichloromethane (100 mL). After nitrogen substitution, DBU (4.9 g, 32.42 mmol) was added and stirred for 30 min. Compound 2b (4.0 g, 24.94 mmol) was then dissolved in dichloromethane (100 mL) and added dropwise to the reaction mixture. The mixture was stirred overnight. The reaction mixture was diluted with dichloromethane (100 mL) and washed with 5% aqueous citric acid (100 mL) and saturated brine (100 mL). The mixture was then dried over anhydrous sodium sulfate, filtered, and spin-dried. Compound 2c (6.1 g, 66.9%) was obtained by silica gel column chromatography (EA:PE = 5:1).

[0510] LC-MS (ESI): m / z = 366.2 [M+H] + .

[0511] Step 3: Compound 2c (6.0 g, 16.42 mmol) was dissolved in a mixed solution of methanol (50 mL) and dichloromethane (20 mL), and (+)-1,2-bis(2S,5S)-2,5-diethylcyclobutanephosphanebenzene(cyclooctadiene)trifluoromethanesulfonate rhodium (0.6 g, 0.84 mmol) was added. The autoclave was filled with hydrogen to a pressure of about 4.0 bar, and stirred at room temperature for 3 h. The solid was filtered off and the reaction solution was concentrated to obtain compound 2d (5.9 g, 98%).

[0512] LC-MS (ESI): m / z = 368.2 [M+H] + .

[0513] Step 4: Compound 2d (5.9 g, 9.08 mmol) was dissolved in a mixed solution of methanol (50 mL) and dichloromethane (20 mL). Palladium on carbon (10%, 1 g) was added and stirred overnight under a hydrogen atmosphere. The solid was then filtered off and the reaction solution was dried to give compound 2e (3.5 g, 93.4%).

[0514] LC-MS (ESI): m / z = 234.1 [M+H] + .

[0515] Step 5: Compound 2e (3.5 g, 15.00 mmol) was dissolved in tetrahydrofuran (35 mL), and lithium hydroxide monohydrate (1.4 g, 59.71 mmol) and water (25 mL) were added. The reaction was stirred at room temperature overnight. Impurities were extracted with ethyl acetate (20 mL x 3), and the pH of the aqueous phase was adjusted to neutral with dilute hydrochloric acid (1N). The product precipitated, filtered, and dried to obtain compound 2f (2.8 g, 85.1%).

[0516] LC-MS (ESI): m / z = 220.1 [M+H] + .

[0517] Step 6: Compound 2f (2.7 g, 12.31 mmol) was dissolved in a mixed solution of acetonitrile (25 mL) and water (25 mL), and sodium bicarbonate (10.3 g, 123.10 mmol) and 9-fluorenylmethyl-N-succinimidyl carbonate (5.0 g, 14.77 mmol) were added. The reaction was stirred at room temperature overnight. After completion of the reaction, dilute hydrochloric acid was added dropwise to adjust the pH to neutral. The mixture was concentrated in vacuo at 40°C to remove most of the acetonitrile, and the solid was collected by filtration to obtain the crude product, which was separated and purified by silica gel chromatography (DCM:MeOH=12:1) to obtain intermediate 2 (1.3 g, 23.9%).

[0518] LC-MS (ESI): m / z = 442.2 [M+H] + .

[0519] 1 H NMR(400MHz,MeOD)δ7.77(d,2H),7.60–7.48(m,2H),7.37(t,2H),7.26(q,2H),6.94–6.78(m, 3H),4.46–4.21(m,2H),4.14(dt,2H),3.13(dd,1H),2.86(dd,1H),2.67(s,4H),1.71(s,4H).

[0520] Intermediate 3:

[0521] Step 1: Dissolve compound 3a (10.0 g, 73.43 mmol) in dichloromethane (100 mL). TiCl4 (25.5 g, 134.38 mmol) was added dropwise to the reaction mixture, and the temperature was cooled to 0°C. After 5 minutes, 1,1-dichlorodimethyl ether (9.4 g, 81.51 mmol) was added dropwise, and the mixture was stirred at 0°C for 3 hours. After the reaction, 200 mL of water was added to the reaction system. The resulting solution was extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography (EA:PE = 1:4) to afford compound 3b (5.58 g, 46.3%).

[0522] LC-MS (ESI): m / z = 163.2 [M+H] + .

[0523] Step 2: Compound 3b (3.0 g, 18.27 mmol), tert-butyl (2-bromoethyl)carbamate (4.9 g, 21.91 mmol), potassium carbonate (5.1 g, 36.54 mmol), and sodium iodide (0.8 g, 5.47 mmol) were dissolved in N,N-dimethylformamide (20 mL) and stirred at 25°C for 16 h. After the reaction, 100 mL of water was added, and the reaction solution was extracted three times with ethyl acetate (50 mL × 3), washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography (EA:PE = 4:1) to afford compound 3c (4.9 g, 87%).

[0524] LC-MS (ESI): m / z = 306.1 [M+H] + .

[0525] Step 3: (±)benzyloxycarbonyl-a-phosphonoglycine trimethyl ester (6.2 g, 18.74 mmol) was dissolved in dichloromethane (100 mL). After nitrogen substitution, DBU (3.1 g, 20.31 mmol) was added and stirred for 30 min. Compound 3c (4.8 g, 15.62 mmol) was then dissolved in dichloromethane (100 mL) and added dropwise to the reaction mixture. The mixture was stirred overnight. The reaction mixture was diluted with dichloromethane (100 mL) and washed with 5% aqueous citric acid (100 mL) and saturated brine (100 mL). The mixture was then dried over anhydrous sodium sulfate, filtered, and spin-dried. Compound 3d (6.1 g, 76.2%) was isolated and purified by silica gel column chromatography (EA:PE = 3:1) to afford compound 3d.

[0526] LC-MS (ESI): m / z = 511.1 [M+H] + .

[0527] Step 4: Compound 3d (6.0 g, 11.71 mmol) was dissolved in a mixed solution of methanol (50 mL) and dichloromethane (20 mL), and (+)-1,2-bis(2S,5S)-2,5-diethylcyclobutanephosphanebenzene(cyclooctadiene)trifluoromethanesulfonate rhodium (0.6 g, 0.83 mmol) was added. The autoclave was filled with hydrogen to a pressure of about 4.0 bar, and stirred at room temperature for 3 h. The solid was filtered off and the reaction solution was concentrated to obtain compound 3e (5.9 g, 98%).

[0528] LC-MS (ESI): m / z = 513.2 [M+H] + .

[0529] Step 5: Compound 3e (5.9 g, 11.46 mmol) was dissolved in a mixed solution of methanol (50 mL) and dichloromethane (20 mL). Palladium on carbon (10%, 1 g) was added and stirred overnight under a hydrogen atmosphere. The solid was then filtered off and the reaction solution was dried to give compound 3f (3.7 g, 84.5%).

[0530] LC-MS (ESI): m / z = 379.4 [M+H] + .

[0531] Step 6: Compound 3f (3.7 g, 9.72 mmol) was dissolved in tetrahydrofuran (25 mL), and lithium hydroxide monohydrate (1.2 g, 48.6 mmol) and water (25 mL) were added. The reaction was stirred at room temperature overnight. Impurities were extracted with ethyl acetate (15 mL x 3). The pH of the aqueous phase was then adjusted to neutral with dilute hydrochloric acid (1N). The product precipitated, filtered, and dried to obtain compound 3g (3.2 g, 89.8%).

[0532] LC-MS (ESI): m / z = 365.2 [M+H] + .

[0533] Step 7: Compound 3g (2.7 g, 7.41 mmol) was dissolved in a mixed solution of acetonitrile (25 mL) and water (25 mL), and sodium bicarbonate (6.2 g, 74.16 mmol) and 9-fluorenylmethyl-N-succinimidyl carbonate (3.3 g, 9.63 mmol) were added. The reaction was stirred at room temperature overnight. After completion of the reaction, dilute hydrochloric acid was added dropwise to adjust the pH to neutral. The mixture was concentrated in vacuo at 40°C to remove most of the acetonitrile, and the solid was collected by filtration to obtain the crude product, which was separated and purified by silica gel chromatography (DCM:MeOH=10:1) to obtain intermediate 3 (2.7 g, 62.1%).

[0534] LC-MS (ESI): m / z = 587.2 [M+H] + .

[0535] 1 H NMR (400MHz, DMSO-d6) δ12.65(s,1H),7.88(d,2H),7.67(s,2H),7.41(d,2H),7.36–7.24(m,2H),7.03–6.88(m,2H),6.65(d ,1H),4.26–4.09(m,4H),3.91(s,2H),3.28(s,2H),2.99(d,1H),2.90–2.68(m,5H),2.51(s,1H),1.98(s,2H),1.39(s,9H).

[0536] Intermediate 4:

[0537] Step 1: Compound 4a (2.0 g, 14.09 mmol) and N-(tert-butyloxycarbonyl)ethanolamine (4.5 g, 28.18 mmol) were dissolved in N,N-dimethylacetamide (20 mL). Potassium carbonate (3.9 g, 28.18 mmol) was added and stirred at 80°C in a microwave oven for 2 h. After the reaction, 20 mL of water was added to the reaction system. The resulting solution was extracted three times with ethyl acetate (40 × 3 times), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography (PE:PE = 4:1) to afford compound 4b (0.9 g, 24.0%).

[0538] LC-MS (ESI): m / z = 267.2 [M+H] + .

[0539] Step 2: (±)benzyloxycarbonyl-a-phosphonoglycine trimethyl ester (6.1 g, 18.47 mmol) was dissolved in dichloromethane (100 mL). After nitrogen substitution, DBU (3.1 g, 20.02 mmol) was added and stirred for 30 min. Compound 4b (4.1 g, 15.40 mmol) was then dissolved in dichloromethane (100 mL) and added dropwise to the reaction mixture. The mixture was stirred overnight. The reaction mixture was diluted with dichloromethane (100 mL) and washed with 5% aqueous citric acid (100 mL) and saturated brine (100 mL). The mixture was then dried over anhydrous sodium sulfate, filtered, and spin-dried. Compound 4c (4.5 g, 62.0%) was obtained by silica gel column chromatography (EA:PE = 3:1).

[0540] LC-MS (ESI): m / z = 472.2 [M+H] + .

[0541] Step 3: Compound 4c (4.4 g, 9.33 mmol) was dissolved in a mixed solution of methanol (40 mL) and dichloromethane (20 mL), and (+)-1,2-bis(2S,5S)-2,5-diethylcyclobutanephosphanebenzene(cyclooctadiene)trifluoromethanesulfonate rhodium (0.6 g, 0.83 mmol) was added. The autoclave was filled with hydrogen to a pressure of about 4.0 bar, and stirred at room temperature for 3 h. The solid was filtered off and the reaction solution was concentrated to obtain compound 4d (4.3 g, 97%).

[0542] LC-MS (ESI): m / z = 474.2 [M+H] + .

[0543] Step 4: Compound 4d (4.3 g, 9.08 mmol) was dissolved in a mixed solution of methanol (50 mL) and dichloromethane (20 mL). Palladium on carbon (10%, 1 g) was added and stirred overnight under a hydrogen atmosphere. The solid was then filtered off and the reaction solution was dried to give compound 4e (2.9 g, 94.1%).

[0544] LC-MS (ESI): m / z = 340.3 [M+H] + .

[0545] Step 5: Compound 4e (3.0 g, 8.84 mmol) was dissolved in tetrahydrofuran (25 mL), and lithium hydroxide monohydrate (0.9 g, 37.6 mmol) and water (25 mL) were added. The reaction was stirred at room temperature overnight. Impurities were extracted with ethyl acetate (20 mL x 3), and the pH of the aqueous phase was adjusted to neutral with dilute hydrochloric acid (1 N). The product precipitated, filtered, and dried to obtain compound 4f (2.4 g, 83.4%).

[0546] LC-MS (ESI): m / z = 326.2 [M+H] + .

[0547] Step 6: Compound 4f (2.4 g, 7.38 mmol) was dissolved in a mixed solution of acetonitrile (20 mL) and water (20 mL). Sodium bicarbonate (6.2 g, 73.8 mmol) and 9-fluorenylmethyl-N-succinimidyl carbonate (3.2 g, 9.59 mmol) were added, and the reaction was stirred at room temperature overnight. After completion of the reaction, dilute hydrochloric acid was added dropwise to adjust the pH to neutral. The mixture was concentrated in vacuo at 40°C to remove most of the acetonitrile, and the solid was collected by filtration to obtain the crude product, which was separated and purified by silica gel column chromatography (DCM:MeOH=10:1) to obtain intermediate 4 (1.9 g, 47.0%).

[0548] LC-MS (ESI): m / z = 548.2 [M+H] + .

[0549] 1 H NMR(400MHz,DMSO-d6)δ12.80(s,1H),8.02(d,1H),7.88(d,2H),7.73(d,1H),7.66–7.58(m,3H),7.41(t,2H),7.30 (dd,2H),6.93(s,1H),6.70(d,1H),4.24–4.09(m,6H),3.26(q,2H),3.02(dd,1H),2.87–2.75(m,1H),1.37(s,9H).

[0550] Intermediate 5:

[0551] Step 1: Compound 5a (5 g, 0.043 mol) was added to trifluoroethanol (50 mL), followed by tert-butyl isocyanide (7.15 g, 0.086 mol) and ammonium acetate (13.3 g, 0.172 mol). The mixture was allowed to react at room temperature for 3 days. TLC indicated completion of the reaction. The reaction solution was concentrated to dryness and purified using a C18 reverse-phase column with mobile phases A and B (35 / 65: acetonitrile and water containing 0.1% TFA) to afford compound 5b (9.5 g, 85% yield).

[0552] LCMS m / z=259.2[M+1] + .

[0553] Step 2: Compound 5b (7.5 g, 0.029 mol) was added to 6N HCl (75 mL) and reacted at 100°C overnight. LCMS indicated complete reaction. The product was concentrated to dryness and purified using a C18 reverse-phase column with mobile phases A and B (5 / 95: acetonitrile and water containing 0.1% TFA) to afford compound 5c (4.6 g, 98% yield).

[0554] LCMS m / z=162.1[M+1] + .

[0555] Step 3: Compound 5c (4.6 g, 0.028 mol) was added to acetonitrile (46 mL) and water (46 mL), followed by the addition of 9-fluorenylmethyl-N-succinimidyl carbonate (Fmoc-Osu) (10.5 g, 0.03 mol) and sodium bicarbonate (24.4 g, 0.28 mol). The reaction was allowed to react at room temperature overnight. LC-MS monitored the reaction completion. The pH was adjusted to 5-6 with 1N HCl, and the acetonitrile was removed by concentration. The mixture was extracted with ethyl acetate (200 mL). The ethyl acetate phase was concentrated to dryness and purified by column chromatography (DCM:MeOH = 10:1) to afford compound 5d (6.3 g, 58% yield).

[0556] LCMS m / z=384.2[M+1] + .

[0557] Step 4: Compound 5d (5.0 g, 0.013 mol) was added to dichloromethane (50 mL), followed by the addition of 85% m-chloroperbenzoic acid (m-CPBA) (7.9 g, 0.039 mol) in portions. The mixture was allowed to react at room temperature overnight. LC-MS confirmed the reaction was complete, and the reaction was quenched with sodium thiosulfate solution (100 mL). The mixture was stirred for 30 min and extracted with ethyl acetate (200 mL). The ethyl acetate phase was concentrated to dryness. Purification by preparative liquid chromatography column chromatography (HPLC conditions: C18 reversed-phase preparative column, mobile phases: deionized water containing 0.1% trifluoroacetic acid (A), acetonitrile containing 0.1% trifluoroacetic acid (B), gradient elution (B content = 5% to 70%), elution time 15 min, flow rate 12 mL / min, column temperature: 30°C, retention time: 8.54 min) to afford intermediate 5 (3.5 g, yield: 64%).

[0558] 1 H NMR(400MHz, CDCl3)δ7.78-7.76(d,2H),7.60-7.58(d,2H),7.43-7.40(t,2H),7.34 -7.31(t,2H),4.52-4.51(d,2H),4.22-4.19(t,1H),3.03(s,4H),2.60-2.50(m,4H).

[0559] LCMS m / z=433.1[M+H2O] + .

[0560] Intermediate 6:

[0561] Step 1: Compound 6a (10.0 g, 51.28 mmol), cyclopropylboronic acid (8.8 g, 102.56 mmol), and cesium carbonate (50.46 g, 153.84 mmol) were added to dioxane (200 mL) and water (40 mL), and 1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (3.8 g, 5.13 mmol) was added. After nitrogen substitution, the mixture was reacted at 80°C overnight. After concentration, the mixture was separated and purified by silica gel chromatography (EA:PE = 5:2) to obtain compound 6b (7.0 g, 86.9%).

[0562] LC-MS (ESI): m / z = 158.1 [M+H] + .

[0563] Step 2: DMF (6.5 g, 89.18 mmol) was added dropwise to phosphorus oxychloride (70 mL) at 0°C. Ten minutes later, compound 6b (7.0 g, 44.59 mmol) was dissolved in phosphorus oxychloride (30 mL) at 0°C, and the mixture was reacted at room temperature for 1 h. The mixture was neutralized with saturated sodium bicarbonate to Ph = 7-8 under ice bath, and extracted with dichloromethane (100 mL × 3). The organic phases were combined and dried, concentrated, and separated and purified by silica gel chromatography (EA: PE = 5:2) to obtain compound 6c (4.5 g, 54.5%).

[0564] LC-MS (ESI): m / z = 186.2 [M+H] + .

[0565] Step 3: Compound 6c (4.5 g, 24.32 mmol) was dissolved in acetonitrile (50 mL), and di-tert-butyl dicarbonate (10.6 g, 48.64 mmol) was added, followed by 4-dimethylaminopyridine (3.6 g, 29.18 mmol). The mixture was reacted at room temperature for 2 h, extracted with dichloromethane (100 mL × 3), and the organic phases were combined and dried by spin drying. After concentration, the mixture was separated and purified by silica gel chromatography (EA:PE = 5:1) to obtain compound 6d (6.0, 86.9%).

[0566] LC-MS(ESI):m / z=230.2[M-56+H] + .

[0567] Step 4: (±)benzyloxycarbonyl-a-phosphonoglycine trimethyl ester (7.0 g, 21.05 mmol) was dissolved in dichloromethane (100 mL). After nitrogen substitution, DBU (6.43 g, 42.3 mmol) was added and stirred for 30 min. Compound 6d (6.0 g, 21.05 mmol) was then dissolved in dichloromethane (100 mL) and added dropwise to the reaction mixture. Stirring was continued overnight. The reaction mixture was diluted with dichloromethane (100 mL) and washed with 5% aqueous citric acid (100 mL) and saturated brine (100 mL). The mixture was then dried over anhydrous sodium sulfate, filtered, and spin-dried. Compound 6e (5.7 g, 55.3%) was obtained by silica gel column chromatography (EA:PE = 3:1).

[0568] LC-MS (ESI): m / z = 491.3 [M+H] + .

[0569] Step 5: Compound 6e (5.7 g, 11.6 mmol) was dissolved in methanol (50 mL), and (+)-1,2-bis(2S,5S)-2,5-diethylcyclobutanephosphanebenzene(cyclooctadiene)trifluoromethanesulfonate rhodium (420 mg, 0.58 mmol) was added. The autoclave was filled with hydrogen to a pressure of about 2.5 MPa, and the mixture was stirred at room temperature overnight. The solid was filtered out, and the reaction solution was concentrated to obtain compound 6f (5.7 g, 99.9%).

[0570] LC-MS (ESI): m / z = 493.2 [M+H] + .

[0571] Step 6: Compound 6f (3.0 g, 6.1 mmol) was dissolved in dichloromethane (50 mL), triethylamine (3.1 g, 30.5 mmol) was added under ice bath, and then

[0572] Iodotrimethylsilane (6.1 g, 30.5 mmol) was stirred at room temperature for 16 h, concentrated at room temperature, and methanol (5 mL) was added to quench the reaction. The product was separated and purified using a C18 reverse phase column (water containing 0.5% TFA: acetonitrile = 3:10) to obtain compound 6g (1.5 g, 95.5%).

[0573] LC-MS (ESI): m / z = 259.1 [M+H] + .

[0574] Step 7: Dissolve compound 6g (1.5g, 5.8mmol) in tetrahydrofuran (20mL), add lithium hydroxide monohydrate (1.58g, 37.7mmol) and water (20mL), and stir the reaction at room temperature for 2h. Then adjust the pH of the aqueous phase to neutral with dilute hydrochloric acid (1N) and proceed directly to the next step.

[0575] LC-MS (ESI): m / z = 245.1 [M+H] + .

[0576] Step 8: Sodium bicarbonate (4.9 g, 58.0 mmol) and 9-fluorenylmethyl-N-succinimidyl carbonate (2.9 g, 8.7 mmol) were added to the reaction solution obtained in the previous step, and the reaction was stirred at room temperature overnight. After completion of the reaction, dilute hydrochloric acid was added dropwise to adjust the pH to 5-6. The product was concentrated in vacuo at 40°C to remove most of the acetonitrile, and extracted with dichloromethane (100 mL × 3). The organic phases were combined and dried, and separated and purified by silica gel column chromatography (DCM:MeOH = 10:1) to obtain intermediate 6 (1.2 g, two-step yield 44.4%).

[0577] LC-MS (ESI): m / z = 467.2 [M+H] + .

[0578] 1 H NMR(400MHz,DMSO-d6)δ10.83(s,1H),7.89–7.85(m,2H),7.63(d,2H),7. 42–7.34(m,3H),7.32–7.24(m,2H),7.16–6.98(m,2H),6.88–6.80(m,1H), 6.60(d,1H),4.22–4.14(m,3H),4.11–4.05(m,1H),3.26–3.19(m,1H),3. 07–2.98(m,1H),2.25–2.15(m,1H),1.00–0.92(m,2H),0.72–0.62(m,2H).

[0579] Intermediate 7 and Intermediate 8:

[0580] Step 1: Compound 7a (20 g, 0.09 mol) was added to methanol (46 mL) and tetrahydrofuran (460 mL), followed by sodium hydroxide (3.6 g, 0.09 mol). The mixture was allowed to react at room temperature for 18 h. LCMS indicated complete reaction. The reaction solution was concentrated to dryness, diluted with water (300 mL), and the pH was adjusted to 5-6 with 1N HCl. The mixture was extracted with ethyl acetate (300 mL). The ethyl acetate phase was concentrated to dryness and purified by column chromatography (DCM:MeOH = 10:1) to afford compound 7b (17.8 g, 95% yield).

[0581] LCMS m / z=207.1[M+1] + .

[0582] Step 2: Compound 7b (17.8 g, 0.086 mol) was added to tetrahydrofuran (1 L), cooled to 0°C, and a solution of borane in dimethyl sulfide (10 mol / L, 10 mL) was added dropwise. The reaction was allowed to proceed for 2 h. LCMS indicated complete reaction of the starting material. Methanol (30 mL) was added dropwise to quench excess borane, and the mixture was concentrated to dryness. The mixture was extracted with ethyl acetate (500 mL) and water (500 mL). The ethyl acetate phase was concentrated to dryness and purified by column chromatography (DCM:MeOH = 10:1) to afford compound 7c (15 g, 91% yield).

[0583] LCMS m / z=215.2[M+23] + .

[0584] Step 3: Pyridine (27.84 g, 0.352 mol) was added to dichloromethane (800 mL), cooled to -20°C, and trifluoromethanesulfonic anhydride (94.8 g, 0.336 mol) was added dropwise. After the addition was complete, 2-bromoethanol (40 g, 0.32 mol) was added to the system, stirred at -20°C for 30 minutes, and concentrated at 30°C to remove dichloromethane. The residue was dissolved in MTBE and filtered. The mother liquor was concentrated to dryness at 25°C. A portion (59.2 g, 0.231 mol) was added to a toluene solution (440 mL) of 7c (14.8 g, 0.077 mol), and DIEA (29.6 g, 0.231 mol) was added. After the addition was complete, the mixture was stirred at 90°C overnight. TLC showed that the reaction of the raw material was complete. The mixture was concentrated to dryness, extracted with ethyl acetate (500 mL) and water (500 mL), and the ethyl acetate phase was concentrated to dryness and purified by column chromatography (PE:EA=2:1) ​​to give compound 7d (21.6 g, yield: 94%).

[0585] Step 4: Compound 7d (21.6 g, 0.072 mol) was added to tetrahydrofuran (430 mL), followed by the addition of lithium aluminum hydride (5.47 g, 0.144 mol) in portions. The mixture was allowed to react at room temperature for 2 h. TLC monitored the reaction to be complete. 5.5 mL of water was slowly added dropwise, followed by 5.5 mL of 15% sodium hydroxide solution, and finally 16.5 mL of water. Anhydrous sodium sulfate was then added, stirred for 30 min, filtered, and the mother liquor was concentrated to dryness to afford 7e (15.9 g, 81% yield).

[0586] LCMS m / z=271.2[M+1] + .

[0587] Step 5: Compound 7e (12.5 g, 0.046 mol) was added to aqueous ammonia (250 mL) and reacted at room temperature for 18 h. TLC monitoring indicated that the reaction of the starting material was not complete. The crude product 7f was directly concentrated to dryness and used for the next reaction.

[0588] LCMS m / z=208.2[M+1] + .

[0589] Step 6: Add the crude compound 7f to acetonitrile (120 mL) and water (120 mL), then add di-tert-butyl dicarbonate (10.0 g, 0.046 mol) and sodium carbonate (9.75 g, 0.092 mol), stir at room temperature for 18 h, concentrate to remove the acetonitrile, extract with ethyl acetate (200 mL), concentrate to dryness, and purify by column chromatography (PE:EA=1:1) to give compound 7g (5.4 g, yield: 38%).

[0590] LCMS m / z=252.2[M+1-56] + .

[0591] Step 7: Compound 7g (5.4 g, 0.017 mol) was added to dichloromethane (54 mL), cooled to 0°C, and carbon tetrabromide (9.7 g, 0.28 mol) and triphenylphosphine (7.7 g, 0.28 mol) were added. The mixture was reacted at room temperature for 18 h. LCMS monitored the reaction for completion. The product was concentrated to dryness and purified by column chromatography (PE:EA = 2:1) to afford 7h (2.4 g, 35% yield).

[0592] LCMS m / z=314.2[M+1-56] + .

[0593] Step 8: Compound 7h (2.4 g, 0.006 mol) was added to DMF (24 mL), followed by dibenzylideneglycine methyl ester (3.15 g, 0.012 mol) and potassium tert-butoxide (1.74 g, 0.015 mol). The mixture was reacted at room temperature for 18 h. LCMS analysis indicated that the starting material had not reacted completely. The mixture was extracted with ethyl acetate (100 mL) and water (100 mL). The ethyl acetate phase was backwashed twice with water, concentrated to dryness, and purified by column chromatography (PE:EA = 1:1) to afford 7i (1.8 g, yield: 51%).

[0594] LCMS m / z=543.2[M+1] + .

[0595] Step 9: Compound 7i (1.8 g, 3.3 mmol) was added to tetrahydrofuran (32 mL), followed by 1N HCl (16 mL). The mixture was allowed to react at room temperature for 1 h. LCMS confirmed the complete reaction. The pH was adjusted to 8-9 with aqueous sodium carbonate solution, and the mixture was extracted with ethyl acetate (100 mL) and water (50 mL). The ethyl acetate phase was concentrated to dryness and purified by column chromatography (DCM:MeOH = 10:1) to afford 7j (1.25 g, 100% yield).

[0596] LCMS m / z=323.2[M+1-56] + .

[0597] Step 10: Compound 7j (1.25 g, 3.3 mmol) was added to methanol (13 mL) and water (4 mL), followed by lithium hydroxide (554 mg, 13.2 mmol). The mixture was reacted at room temperature for 4 h. LCMS confirmed the complete reaction. The reaction mixture was used directly in the next step.

[0598] LCMS m / z=309.2[M+1-56] + .

[0599] Step 11: The pH of the reaction mixture from the previous step was adjusted to 5-6 with 1N HCl, and then to 8-9 with aqueous sodium bicarbonate. 9-Fluorenylmethyl-N-succinimidyl carbonate (1.3 g, 3.96 mmol) and sodium bicarbonate (2.77 g, 33 mmol) were then added and stirred at room temperature for 2 h. LCMS indicated that the reaction was complete. The pH was adjusted to 7 with 1N HCl, and the mixture was extracted with ethyl acetate (100 mL) and water (100 mL). The ethyl acetate phase was concentrated to dryness and purified by column chromatography (DCM:MeOH = 10:1) to obtain 1.8 g of the racemate. The racemate was subjected to chiral resolution using an SFC Prep 150AP instrument and a Daicel AD-H column (19 mm × 250 mm). The sample was dissolved in methanol and filtered through a 0.45 μm filter to prepare a sample solution. Preparative chromatography conditions: Mobile phase A, B composition: Mobile phase A: CO2; Mobile phase B: methanol; Isocratic elution, mobile phase B content 25%; Flow rate 40 ml / min. Intermediate 7 (P1) (730 mg, yield: 38%) was obtained in 4.1 minutes, and Intermediate 8 (P2) (750 mg, yield: 39%) was obtained in 4.6 minutes.

[0600] Intermediate 7 1 H NMR (400MHz, CDCl3) δ7.77-7.75(d,2H),7.60-7.57(t,2H),7.41-7.37(t,2H),7.32-7.29(t,2H),4.49-4.41(m,3H),4.23-4.20(t,1H),3.73 -3.68(m,6H),3.59-3.55(m,2H),3.51-3.49(m,2H),3.31-3.27(m,2H),2.22-2.04(m,2H),1.45(s,9H).

[0601] LCMS m / z=487.2[M+1-100] + .

[0602] Intermediate 81 H NMR (400MHz, CDCl3) δ7.75-7.73(d,2H),7.59-7.56(t,2H),7.39-7.36(t,2H),7.30-7.27(t,2H),4.47-4.39(m,3H),4.22 -4.19(t,1H),3.70-3.64(m,6H),3.57-3.53(m,2H),3.51-3.49(m,2H),3.31-3.27(m,2H),2.20-2.03(m,2H),1.44(s,9H).

[0603] LCMS m / z=487.2[M+1-100] + .

[0604] Intermediate 9 and Intermediate 10:

[0605] Step 1: Compound 9a (10.4 g, 70.5 mmol) was dissolved in tetrahydrofuran (200 mL). After nitrogen replacement, tetraisopropyl titanate (4 ml, 13.6 mmol) and ethylmagnesium bromide (58.67 ml, 176 mmol) were added dropwise at zero degrees Celsius. The temperature was raised to room temperature and the reaction was allowed to react overnight. After the reaction was completed, water was added at zero degrees Celsius to quench the reaction. The mixture was extracted with ethyl acetate, and the organic phases were combined and dried. After concentration, the mixture was separated and purified using a silica gel column chromatography (EA:PE = 1:5) to obtain compound 9b (7.0 g, 71%).

[0606] 1 H NMR (400MHz, CDCl3) δ = 4.68 (t, 1H), 3.47 (s, 1H), 3.39 (s, 6H), 1.88 (d, 2H), 0.77 (t, 2H), 0.45 (t, 2H).

[0607] Step 2: Compound 9b (7.0 g, 47.95 mmol) was dissolved in dichloromethane (50 ml), triethylamine (14.53 g, 143.85 mmol) was added, and methanesulfonyl chloride (6.59 g, 57.54 mmol) was added dropwise at zero degrees. The reaction was carried out at room temperature for 1 h, and water was added to quench the reaction under ice bath. The reaction was extracted with dichloromethane, and the organic phases were combined and dried, and concentrated to obtain the crude product of compound 9c.

[0608] 1 H NMR (400MHz, CDCl3) δ = 4.69 (t, 1H), 3.37 (s, 6H), 3.01 (s, 3H), 2.15 (d, 2H), 1.30-1.26 (m, 2H), 0.81 (d, 2H).

[0609] Step 3: The crude compound 9c from the previous step was dissolved in tetrahydrofuran / water (60 mL / 30 ml), and potassium peroxymonosulfonate (24.91 g, 71.93 mmol) was added at zero degrees. The reaction was allowed to react at room temperature overnight, and the mixture was extracted with ethyl acetate. The organic phases were combined and dried, and recrystallized from methyl tert-butyl ether to obtain compound 9d (4.8 g, two-step yield 52%).

[0610] LC-MS (ESI): m / z = 195.1 [M+H] + .

[0611] Step 4: Compound 9d (7.0 g, 36.08 mmol) was dissolved in 1,2-dichloroethane (200 mL). After nitrogen replacement, thionyl chloride (3.26 ml, 45 mmol) was added and refluxed for 1 hour. After cooling to room temperature, NCS (7.2 g, 54.12 mmol) and 10 drops of 4M hydrogen chloride-1,4-dioxane were added, and the mixture was refluxed overnight. After cooling to room temperature, methanol (25 ml) was added and the reaction was continued for 1 hour. After the reaction was completed, the mixture was directly concentrated and dried. Chloroform was added at zero degrees, the liquid was collected by filtration, and concentrated to obtain a crude compound 9e.

[0612] LC-MS (ESI): m / z = 243.1 [M+H] +

[0613] Step 5: The crude compound 9e was dissolved in dichloromethane (20 mL), and triethylamine (5.47 g, 54.12 mmol) was added at zero degrees. Stirring was continued at this temperature for 3 h, quenched with water, extracted with dichloromethane, and the organic phases were combined and concentrated. The mixture was separated and purified by silica gel chromatography (EA:PE = 1:5) to give compound 9f (3.5 g, two-step yield 66%).

[0614] LC-MS (ESI): m / z = 147.1 [M+H] +

[0615] Step 6: Compound 9f (3.0 g, 20.55 mmol) was dissolved in acetonitrile (50 mL), and sodium bicarbonate (17.26 g, 205.5 mmol) was added, followed by thioacetamide (1.54 g, 20.55 mmol). The mixture was stirred at 80°C for 5 h, filtered, concentrated, and purified by silica gel column chromatography (EA:PE = 1:1) to give compound 9g (3 g, 79%).

[0616] LC-MS (ESI): m / z = 186.2 [M+H] + .

[0617] Step 7: Compound 9g (1 g, 5.38 mmol) was placed in a 50 ml round-bottom flask, 3 M hydrochloric acid solution (10 mL) was added, and the mixture was stirred at 100°C for 5 h. After the reaction was completed, the mixture was extracted with methyl tert-butyl ether, and the aqueous phase was directly concentrated to obtain compound 9h hydrochloride.

[0618] LC-MS (ESI): m / z = 148.2 [M+H] + .

[0619] Step 8: Compound 9h (1 g, 6.8 mmol) was placed in a 50 ml round-bottom flask, and trifluoroacetic acid (5 ml) and triphenylmethanol (2.12 g, 8.16 mmol) were added. The mixture was stirred at room temperature for 10 min and dried to obtain the target compound 9i, which was directly used for the next step.

[0620] LC-MS (ESI): m / z = 388.5 [MH] + .

[0621] Step 8: Dissolve the crude compound 9i from the previous step in acetonitrile and water (50 ml / 10 ml), add sodium bicarbonate (5.7 g, 68 mmol) and 9-fluorenylmethyl-N-succinimidyl carbonate (3.44 g, 10.2 mmol), stir at room temperature for 3 h, filter, add saturated brine (30 ml), extract with ethyl acetate, combine the organic phases, concentrate, and purify by silica gel column chromatography (DCM:MeOH = 10:1) to obtain 2.2 g of the racemate, with a two-step yield of 43%. The racemate was subjected to chiral resolution using an SFC Prep 150AP instrument and a Daicel AD-H column (19 mm × 250 mm). The sample was dissolved in methanol and filtered through a 0.45 μm filter to prepare a sample solution. Preparative chromatography conditions: Mobile phase A, B composition: Mobile phase A: CO2; Mobile phase B: methanol; isocratic elution, mobile phase B content 25%, flow rate 40 ml / min. Intermediate 9 (P1) (890 mg) was obtained in 3.8 min and intermediate 10 (P2) (910 mg) was obtained in 4.2 min.

[0622] Intermediate 9:

[0623] 1H NMR(400MHz, CDCl3)δ=7.78(d,2H),7.61–7.49(m,8H),7.42–7.39(m,2H),7.34–7.30(m,2H),7.28–7.22(m,6H),7.22–7.14(m,3H) ,5.00(d,1H),4.34(d,2H),4.19(t,1H),3.88(d,1H),1.06–0.92(m,1H),0.85–0.75(m,1H),0.75–0.63(m,1H),0.28–0.19(m,1H).

[0624] Intermediate 10:

[0625] 1 H NMR(400MHz, CDCl3)δ=7.77(d,2H),7.59–7.54(m,8H),7.42–7.39(m,2H),7.33–7.30(m,2H),7.26–7.22(m,6H),7.21–7.13(m,3H) ,5.00(d,1H),4.34(d,2H),4.19(t,1H),3.89(d,1H),1.02–0.97(m,1H),0.86–0.74(m,1H),0.73–0.62(m,1H),0.26–0.20(m,1H).

[0626] Intermediate 11:

[0627] Step 1: Compound 11a (20.0 g, 59.6 mmol) was dissolved in ethyl acetate (150 mL). Cyclohexane (75 ml) and tert-butyl trichloroacetimidate (32.5 g, 149 mmol) were added at room temperature. The temperature was raised to 30°C and the reaction was continued for 48 hours. After the reaction was completed, the mixture was concentrated under reduced pressure. The crude product was separated and purified by silica gel column chromatography (EA:PE = 10:90) to obtain compound 11b (23.2 g, 99.4%).

[0628] 1 H NMR(400MHz,Chloroform-d)δ7.76(d,2H),7.61(d,2H),7.39(t,2H),7.31(t,2H) ,5.67(d,1H),4.40(ddd,3H),4.24(t,1H),2.76(t,2H),2.04(d,1H),1.50(s,9H).

[0629] Step 2: Compound 11b (10.0 g, 25.5 mmol) was dissolved in dry N,N-dimethylformamide (200 ml). Silver nitrate (434 mg, 2.55 mmol) and N-bromosuccinimide (5.46 g, 30.7 mmol) were added and allowed to react overnight at room temperature. After completion of the reaction, the mixture was quenched with water (500 mL) and extracted with ethyl acetate (200 mL x 5). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the crude product, which was purified by silica gel column chromatography (EA:PE = 10:90) to afford 11c (10.5 g, 87.4%).

[0630] LC-MS (ESI): m / z = 470.1 [M+H] + .

[0631] Step 3: Compound 11d (9.00 g, 55.8 mmol) was dissolved in dichloromethane (400 mL) at 0°C. Imidazole (4.94 g, 72.6 mmol), iodine (18.4 g, 72.6 mmol), and triphenylphosphine (19.0 g, 72.6 mmol) were added. The mixture was allowed to warm to room temperature and react overnight. After completion of the reaction, the mixture was quenched with saturated aqueous sodium thiosulfate (100 mL) and water (500 mL). The mixture was extracted with ethyl acetate (200 mL x 5). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the crude product, which was purified by silica gel column chromatography (EA:PE = 50:50) to afford 11e (8.90 g, 63.6%).

[0632] LC-MS (ESI): m / z = 272.0 [M+H] + .

[0633] Step 4: Zinc powder (2.43 g, 37.2 mmol) and iodine (94.5 mg, 0.372 mmol) were added to a round-bottom flask and heated with a heat gun under nitrogen for 5 minutes. After cooling to room temperature, nitrogen was applied three times. After cooling to 0°C, a solution of compound 11e (3.17 g, 11.7 mmol) in DMF (50 mL) was added by injection and the mixture was warmed to room temperature for about 2 hours. Cuprous cyanide (950 mg, 10.6 mmol) and lithium chloride (900 mg, 21.2 mmol) were added to a round-bottom flask. The mixture was heated to 150°C under nitrogen for 2 hours. After cooling to room temperature, DMF (10 mL) was added by injection and stirring continued for 10 minutes. After cooling to -15°C, a solution of zinc-activated compound 11e in DMF was added by injection. Five minutes later, a solution of compound 11c (5.00 g, 10.6 mmol) in DMF (40 mL) was added by injection. The mixture was then warmed to room temperature and stirred overnight. After completion of the reaction, the mixture was quenched with water (500 mL) and extracted with ethyl acetate (200 mL x 5). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the crude product, which was purified by silica gel column chromatography (EA:PE = 70:30) to afford 11f (3.47 g, 61.1%).

[0634] LC-MS (ESI): m / z = 535.3 [M+H] + .

[0635] Step 5: Dissolve compound 11f (3.47 g, 6.49 mmol) in ethyl acetate (200 ml), add palladium / carbon (2.0 g), insert a hydrogen balloon, and react at room temperature overnight. After TLC monitoring, the starting material disappears and the solid is removed by filtration and washed with ethyl acetate. The combined organic phases are then concentrated to yield crude compound 11g (3.21 g).

[0636] LC-MS (ESI): m / z = 539.3 [M+H] + .

[0637] Step 6: Dissolve the crude compound 11g (3.21 g) in 1,2-dichloroethane (200 mL), add trimethyltin hydroxide (4.31 g, 23.8 mmol), and heat to 70°C overnight. After completion of the reaction, cool the temperature to room temperature and concentrate under reduced pressure. The crude product is purified by silica gel column chromatography (DCM:MeOH = 80:20) to afford compound 11h (2.90 g, 85.2% yield over two steps).

[0638] LC-MS (ESI): m / z = 525.3 [M+H] + .

[0639] Step 7: Compound 11h (2.90 g, 5.53 mmol) was dissolved in dry N,N-dimethylformamide (150 ml), and sodium carbonate (2.34 g, 22.1 mmol) and 3-bromopropylene (2.01 g, 16.6 mmol) were added. The mixture was allowed to react at room temperature for 3 days. After completion of the reaction, the mixture was quenched with water (500 mL) and extracted with ethyl acetate (200 mL x 5). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the crude product, which was purified by silica gel column chromatography (EA:PE = 70:30) to afford 11i (2.41 g, 77.2%).

[0640] LC-MS (ESI): m / z = 565.3 [M+H] + .

[0641] Step 8: Compound 11i (2.41 g, 4.27 mmol) was dissolved in a mixed solvent of dichloromethane (50 mL) and trifluoroacetic acid (50 mL) and reacted at room temperature. After completion of the reaction, monitored by TLC, the mixture was concentrated under reduced pressure. The crude product was redissolved in dichloromethane (100 mL) and the pH was adjusted to approximately 7 with saturated aqueous sodium bicarbonate. Water was added and the mixture was extracted with dichloromethane (100 mL x 5). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to obtain the crude product, which was then slurried in dichloromethane to afford Intermediate 11 (1.69 g, 77.9%).

[0642] 1 H NMR(400MHz, Methanol-d4)δ7.79(d,2H),7.67(t,2H),7.39(t,2H),7.31(td,2H),6.01–5.88(m,1H),5.33(dq,1H),5.22(dq,1H),4.62(dq, 2H),4.42–4.33(m,3H),4.23(t,1H),4.13(dd,1H),3.26–3.19(m,1H), 1.98(s,3H),1.89–1.77(m,2H),1.75–1.62(m,2H),1.46–1.37(m,4H).

[0643] LC-MS (ESI): m / z = 509.2 [M+H] + .

[0644] Example 1:

[0645] Step 1: The synthesis of 1B was carried out using standard Fmoc chemistry:

[0646] 1. Add Rink Amide MBHA Resin (1 mmol, 1.4 g, sub: 0.7 mmol / g) and dichloromethane solvent to the reactor, swell for 30 minutes, add 20% piperidine / DMF, and mix for 30 minutes.

[0647] 2. Drain and rinse five times with DMF.

[0648] 3. Add Fmoc-Sar-OH protected amino acid solution, mix for 30 seconds, then add coupling reagent, bubble nitrogen for 1.5 hours, and monitor the reaction with ninhydrin.

[0649] 4. Drain and rinse three times with DMF.

[0650] 5. Add 20% piperidine / DMF and mix for 30 minutes.

[0651] 6. Drain and rinse five times with DMF.

[0652] 7. Add Fmoc-protected amino acid solution, mix for 30 seconds, then add coupling reagent, bubble nitrogen for 1.5 hours, and monitor the reaction with ninhydrin.

[0653] 8. Drain and rinse three times with DMF

[0654] 9. Repeat steps 5-8 for the next amino acid coupling.

[0655] 10. In the last step, the product was washed twice with MeOH, once with DCM, and twice with MeOH, and dried under vacuum to obtain peptide resin 1B (6.5 g), which was used directly in the next reaction.

[0656] Step 2: Add 60 ml of lysis buffer (91% trifluoroacetic acid + 4% triisopropylsilane + 3% 1,2-ethanedithiol + 2% water) to a 100 ml reaction flask, stir well, then add peptide resin 1B (6.5 g), and stir at room temperature for 2 hours. Filter the resin to obtain a filtrate, which is added to 500 ml of methyl tert-butyl ether (methyl tert-butyl ether cooled to 0°C in advance). White flocculent material precipitates and centrifuges (3 min at 3000 rpm). The white precipitate is washed three times with methyl tert-butyl ether and vacuum dried to obtain crude peptide 1C (2.4 g) as an off-white solid, which is used directly in the next reaction.

[0657] LCMS m / z=627.6[M / 3+H] + ,940.9[M / 2+H] +

[0658] Step 3: To a 2L reaction flask, add water (750ml), acetonitrile (250ml), and 1C (2g, 1.06mmol) in sequence. After stirring, slowly add iodine / acetonitrile solution (0.1mol / L) dropwise until the reaction solution turns pale yellow. Add ascorbic acid for quenching and purify by preparative HPLC. Separation method: 1. Apparatus: Waters 2767 Preparative HPLC; Chromatographic column: SunFire@PrepC18 (19mm×250mm). 2. Filter the sample through a 0.45μm filter to prepare a sample solution. 3. Preparative chromatography conditions: a. Mobile phase A, B composition: A: 0.1% trifluoroacetic acid / H2O, B: CH3CN; b. Gradient elution: mobile phase content 5%-45%; c. Flow rate: 12ml / min; d. Elution time: 30min, retention time: 16min. Lyophilization afforded compound 1 (400mg, 99% purity).

[0659] LCMS m / z=626.9[M / 3+H] + ,939.9[M / 2+H] +

[0660] Example 2:

[0661] Step 1: 2B was synthesized using standard Fmoc chemistry:

[0662] 1. Add Rink Amide MBHA Resin (1 mmol, 1.4 g, sub: 0.7 mmol / g) and dichloromethane solvent to the reactor, swell for 30 minutes, add 20% piperidine / DMF, and mix for 30 minutes.

[0663] 2. Drain and rinse five times with DMF.

[0664] 3. Add Fmoc-Sar-OH protected amino acid solution, mix for 30 seconds, then add coupling reagent, bubble nitrogen for 1.5 hours, and monitor the reaction with ninhydrin.

[0665] 4. Drain and rinse three times with DMF.

[0666] 5. Add 20% piperidine / DMF and mix for 30 minutes.

[0667] 6. Drain and rinse five times with DMF.

[0668] 7. Add Fmoc-protected amino acid solution, mix for 30 seconds, then add coupling reagent, bubble nitrogen for 1.5 hours, and monitor the reaction with ninhydrin.

[0669] 8. Drain and rinse three times with DMF

[0670] 9. Repeat steps 5-8 for the next amino acid coupling.

[0671] 10. In the last step, the product was washed twice with MeOH, once with DCM, and twice with MeOH, and dried under vacuum to obtain peptide resin 2B (6.3 g), which was used directly in the next reaction.

[0672] Step 2: Add 60 ml of lysis buffer (91% trifluoroacetic acid + 4% triisopropylsilane + 3% 1,2-ethanedithiol + 2% water) to a 100 ml reaction flask, stir well, then add peptide resin 2B (6.3 g), and stir at room temperature for 2 hours. Filter the resin to obtain a filtrate, which is added to 500 ml of methyl tert-butyl ether (methyl tert-butyl ether cooled to 0°C in advance). White flocculent material precipitates and centrifuges (3 min at 3000 rpm). The white precipitate is washed three times with methyl tert-butyl ether and vacuum dried to obtain crude peptide 2C (2.5 g) as an off-white solid, which is used directly in the next reaction.

[0673] LCMS m / z=637.3[M / 3+H] + ,955.4[M / 2+H] +

[0674] Step 3: In a 2L reaction bottle, add water (750ml), acetonitrile (250ml), and 2C (2g, 1.06mmol) in sequence. After stirring evenly, slowly add iodine / acetonitrile solution (0.1mol / L) until the reaction solution turns light yellow. Add ascorbic acid to quench and prepare HPLC purification. Separation method: 1. Instrument: waters2767 preparative liquid phase; chromatographic column: SunFire@PrepC18 (19mm×250mm). 2. The sample is filtered with a 0.45μm filter to prepare a sample solution. 3. Preparative chromatography conditions: a. Mobile phase A, B composition: A: 0.1% trifluoroacetic acid / H2O, B: CH3CN; b. Gradient elution: mobile phase content 5%-45%; c. Flow rate: 12ml / min; d. Elution time: 30min, retention time: 16min. Lyophilization gave compound 2 (410mg, purity 99%)

[0675] LCMS m / z=636.6[M / 3+H] + ,954.4[M / 2+H] +

[0676] Example 3:

[0677] Using the above materials as raw materials, the synthetic method of compound 1 was used to obtain compound 3 (50 mg, purity 95%)

[0678] LCMS m / z=961.0[M / 2+H] +

[0679] Example 4:

[0680] Using the above materials as raw materials, compound 4 (50 mg, purity 99%) was obtained by the method of compound 1.

[0681] LCMS m / z=961.5[M / 2+H] + .

[0682] Example 5:

[0683] Using the above materials as raw materials, compound 5 (50 mg, purity 95%) was obtained by the method of compound 1.

[0684] LCMS m / z=950.3[M / 2+H] + .

[0685] Example 6:

[0686] Using the above materials as raw materials, compound 6 (50 mg, purity 94%) was obtained by the method of compound 1.

[0687] LCMS m / z=963.4[M / 2+H] + .

[0688] Example 7:

[0689] Step 1: 7B was synthesized using standard Fmoc chemistry:

[0690] 1. Add Rink Amide MBHA Resin (1 mmol, 1.4 g, sub: 0.7 mmol / g) and dichloromethane solvent to the reactor, swell for 30 minutes, add 20% piperidine / DMF, and mix for 30 minutes.

[0691] 2. Drain and rinse five times with DMF.

[0692] 3. Add Fmoc-Sar-OH protected amino acid solution, mix for 30 seconds, then add coupling reagent, bubble nitrogen for 1.5 hours, and monitor the reaction with ninhydrin.

[0693] 4. Drain and rinse three times with DMF.

[0694] 5. Add 20% piperidine / DMF and mix for 30 minutes.

[0695] 6. Drain and rinse five times with DMF.

[0696] 7. Add Fmoc-protected amino acid solution, mix for 30 seconds, then add coupling reagent, bubble nitrogen for 1.5 hours, and monitor the reaction with ninhydrin.

[0697] 8. Drain and rinse three times with DMF

[0698] 9. Repeat steps 5-8 for the next amino acid coupling.

[0699] 10. In the last step, the product was washed twice with MeOH, once with DCM, and twice with MeOH, and dried under vacuum to obtain peptide resin 7B (6 g), which was used directly in the next reaction.

[0700] Step 2: Add 50 ml of lysis buffer (91% trifluoroacetic acid + 4% triisopropylsilane + 3% 1,2-ethanedithiol + 2% water) to a 100 ml reaction flask, stir well, then add peptide resin 7B (6 g), and stir at room temperature for 2 hours. Filter the resin to obtain a filtrate, which is added to 300 ml of methyl tert-butyl ether (methyl tert-butyl ether cooled to 0°C in advance). White flocculent material precipitates and centrifuges (3 min at 3000 rpm). The white precipitate is washed three times with methyl tert-butyl ether and vacuum dried to obtain crude peptide 7C (2.2 g) as an off-white solid, which is used directly in the next reaction.

[0701] LCMS m / z=655.2[M / 3+H] + ,982.1[M / 2+H] +

[0702] Step 3: To a 2L reaction flask, add water (750ml), acetonitrile (250ml), and 7C (2g, 1.02mmol) in sequence. After stirring, slowly add iodine / acetonitrile solution (0.1mol / L) dropwise until the reaction solution turns pale yellow. Quench with ascorbic acid and purify by preparative HPLC. Separation method: 1. Apparatus: Waters 2767 Preparative HPLC; Chromatographic column: SunFire@PrepC18 (19mm×250mm). 2. Filter the sample through a 0.45μm filter to prepare a sample solution. 3. Preparative chromatography conditions: a. Mobile phase A, B composition: A: 0.1% trifluoroacetic acid / H2O, B: CH3CN; b. Gradient elution: mobile phase content 5%-45%; c. Flow rate: 12ml / min; d. Elution time: 30min, retention time: 16min. Compound 7 (50mg, 98% purity) was obtained.

[0703] LCMS m / z=981.0[M / 2+H] + .

[0704] Example 8:

[0705] Using the above materials as raw materials, compound 8 (50 mg, purity 99%) was obtained by the method of compound 1.

[0706] LCMS m / z=950.3[M / 2+H] + .

[0707] Example 9:

[0708] Using the above materials as raw materials, compound 9 (25 mg, purity 97%) was obtained by the method of compound 1.

[0709] LCMS m / z=973.6[M / 2+H] + .

[0710] Example 10

[0711] Step 1: Using the above materials as raw materials, compound 10B was obtained by the method of compound 1.

[0712] Step 2: 30 ml of dichloromethane was added to a solid-phase synthesis reactor, followed by phenylsilane (1 g) and tetrakis(triphenylphosphine)palladium (462 mg). The mixture was reacted under nitrogen atmosphere for 8 hours. The resin was washed with dichloromethane 5 times, N,N-dimethylformamide 5 times, and 0.5% sodium diethyldithiocarbamate solution in N,N-dimethylformamide for 15 min + 15 min, and then washed three times with N,N-dimethylformamide to obtain peptide resin 10C.

[0713] Step 3: Add 2% hydrazine hydrate solution in N,N-dimethylformamide into the reactor and react for 30 min+30 min, then wash with N,N-dimethylformamide solution 5 times to obtain peptide resin 10D.

[0714] Step 4: N-methylpyrrolidone (20 ml), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (417.2 mg, 1.1 mmol), and DIEA (0.19 ml, 1.1 mmol) were added to a solid-phase synthesis reactor and reacted at room temperature for 16 h. The mixture was monitored by ninhydrin to obtain a colorless state. The solvent was drained and the resin was washed with N,N-dimethylformamide 3 times, methanol 2 times, dichloromethane 1 time, and methanol 2 times. The peptide resin 10E (5.2 g) was obtained after vacuum drying.

[0715] Step 5: Add 60 ml of lysis buffer (91% trifluoroacetic acid + 4% triisopropylsilane + 3% 1,2-ethanedithiol + 2% water) to a 100 ml reaction flask, stir thoroughly, then add peptide resin 10E (5.2 g) and stir at room temperature for 2 hours. Filter the resin to obtain a filtrate, which is then added to 500 ml of methyl tert-butyl ether (pre-cooled to 0°C). A white flocculent solid precipitates and is centrifuged (3 min at 3000 rpm). The white precipitate is washed three times with methyl tert-butyl ether and dried under vacuum to obtain an off-white solid of crude peptide compound 10 (1.8 g). Purify by preparative HPLC. Separation method: 1. Instrument: Waters 2767 preparative liquid chromatography; Column: SunFire@PrepC18 (19 mm × 250 mm). 2. Filter the sample through a 0.45 μm filter to prepare a sample solution. 3. Preparative chromatography conditions: a. Mobile phases A and B: A: 0.1% trifluoroacetic acid / H2O, B: CH3CN; b. Gradient elution: mobile phase content 5%-45%; c. Flow rate: 12 ml / min; d. Elution time: 30 min, retention time: 17 min. Lyophilization afforded Compound 10 (25 mg, 91.9% purity) as a white solid.

[0716] LCMS m / z=1821.3[M+H] + .

[0717] Example 11:

[0718] Step 1: Using the above materials as raw materials, compound 11B was obtained using the method of compound 1.

[0719] Step 2: Add 30 ml of dichloromethane to a solid-phase synthesis reactor, followed by phenylsilane (1 g) and tetrakis(triphenylphosphine)palladium (462 mg), and react under nitrogen for 8 hours. Wash the resin with dichloromethane 5 times, N,N-dimethylformamide 5 times, and 0.5% sodium diethyldithiocarbamate solution in N,N-dimethylformamide for 15 min + 15 min, and then wash three times with N,N-dimethylformamide to obtain peptide resin 11C.

[0720] Step 3: Add 20% piperidine in N,N-dimethylformamide solution into the reactor and react for 30 minutes. Wash with N,N-dimethylformamide solution 5 times to obtain peptide resin 11D.

[0721] Step 4: N-methylpyrrolidone (20 ml), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (417.2 mg, 1.1 mmol), and DIEA (0.19 ml, 1.1 mmol) were added to a solid-phase synthesis reactor and reacted at room temperature for 16 h. The mixture was monitored by ninhydrin and turned colorless. The solvent was drained and the resin was washed with N,N-dimethylformamide 3 times, methanol 2 times, dichloromethane 1 time, and methanol 2 times. The peptide resin 11E was obtained by vacuum drying.

[0722] Step 5: Add 50 ml of lysis buffer (91% trifluoroacetic acid + 4% triisopropylsilane + 3% 1,2-ethanedithiol + 2% water) to a 100 ml reaction flask, stir thoroughly, then add peptide resin 11E (5 g), and stir at room temperature for 2 hours. Filter the resin to obtain a filtrate, which is added to 500 ml of methyl tert-butyl ether (pre-cooled to 0°C). White flocculent material precipitates and is centrifuged (3 min at 3000 rpm). The white precipitate is washed three times with methyl tert-butyl ether and dried under vacuum to obtain crude peptide 11F (1.5 g) as an off-white solid.

[0723] Step 6: To a 2L reaction flask, add water (1050ml), acetonitrile (450ml), and 11F (1.5g, 0.76mmol) in sequence. After stirring, slowly add iodine / acetonitrile solution (0.1mol / L) dropwise until the reaction solution turns pale yellow. Add ascorbic acid for quenching and purify by preparative HPLC. Separation method: 1. Apparatus: Waters 2767 preparative liquid chromatography; chromatographic column: SunFire@PrepC18 (19mm×250mm). 2. Filter the sample through a 0.45μm filter to prepare a sample solution. 3. Preparative chromatography conditions: a. Mobile phase A, B composition: A: 0.1% trifluoroacetic acid / H2O, B: CH3CN; b. Gradient elution: mobile phase content 5%-45%; c. Flow rate: 12ml / min; d. Elution time: 30min, retention time: 16min. Lyophilization afforded compound 11 (28mg, 99% purity) as a white solid.

[0724] LCMS m / z=987.5[M / 2+H] + 658.8[M / 3+H] + .

[0725] Example 12:

[0726] Using the above materials as raw materials, compound 12 (300 mg, purity 98%) was obtained by the method of compound 1.

[0727] LCMS m / z=967.5[M / 2+H] + 645.5[M / 3+H] + .

[0728] Example 13:

[0729] Using the above materials as raw materials, compound 13 (350 mg, purity 98%) was obtained by the method of compound 1.

[0730] LCMS m / z=953.1[M / 2+H] + 635.9[M / 3+H] + .

[0731] Example 14:

[0732] Using the above materials as raw materials, compound 14 (8 mg, purity 95%) was obtained by the synthesis method of compound 1.

[0733] LCMS m / z=963.4[M / 2+H] + 642.7[M / 3+H] + .

[0734] Example 15:

[0735] Using the above materials as raw materials, compound 15 (130 mg, purity 98%) was obtained by the method of compound 1.

[0736] LCMS m / z=984.2[M / 2+H] + ,656.3[M / 3+H] + .

[0737] Example 16:

[0738] Using the above materials as raw materials, compound 16 (400 mg, purity 94%) was obtained by the method of compound 1.

[0739] LCMS m / z=997.4[M / 2+H] + ,665.2[M / 3+H] + .

[0740] Example 17:

[0741] Using the above materials as raw materials, compound 17 (40 mg, purity 93%) was obtained by the method of compound 1.

[0742] LCMS m / z=984.0[M / 2+H] + ,656.5[M / 3+H] + .

[0743] Example 18:

[0744] Using the above materials as raw materials, compound 18 (40 mg, purity 94%) was obtained by the method of compound 1.

[0745] LCMS m / z=984.0[M / 2+H] + ,656.5[M / 3+H] + .

[0746] Example 19:

[0747] Using the above materials as raw materials, compound 19C (1.5 g) was obtained by the method of compound 1.

[0748] Step 3: To a 3 L reaction flask, add water (1050 ml), acetonitrile (450 ml), and 19C (1.5 g, 0.8 mmol) in sequence. After stirring, add 1,3,5-tris(bromomethyl)benzene (0.26 g, 0.8 mmol). Adjust the pH to 8 with ammonium bicarbonate. React for 16 h before preparative HPLC purification. Separation Method: 1. Apparatus: Waters 2767 Preparative HPLC; Column: SunFire@PrepC18 (19 mm × 250 mm). 2. Filter the sample through a 0.45 μm filter to prepare a sample solution. 3. Preparative Chromatography Conditions: a. Mobile Phase A, B Composition: A: 0.1% trifluoroacetic acid / H2O, B: CH3CN; b. Gradient Elution: Mobile Phase Content 5%-45%; c. Flow Rate: 12 ml / min; d. Elution Time: 30 min, Retention Time: 17 min. Freeze-drying gave compound 19 (50 mg, purity 97%) as a white solid.

[0749] LCMS m / z=1001.5[M / 2+H] + ,667.8[M / 3+H] + .

[0750] Example 20:

[0751] Using the above materials as raw materials, compound 20 (40 mg, purity 96%) was obtained by the method of compound 1.

[0752] LCMS m / z=890.1[M / 3+H] + .

[0753] Example 21:

[0754] Using the above materials as raw materials, solid phase synthesis was performed using the method of compound 1 to step 14, and then Dde was removed using 2% hydrazine hydrate / DMF. Then, the method of compound 1 was used to continue synthesis to obtain compound 21 (30 mg, purity 97%).

[0755] LCMS m / z=904.0[M / 3+H] + .

[0756] Example 22:

[0757] Using the above materials as raw materials, compound 22 (15 mg, purity 87%) was obtained by the method of compound 10.

[0758] LCMS m / z=908.7[M / 2+H] + .

[0759] Example 23:

[0760] Using the above materials as raw materials, the solid phase synthesis method of compound 1 was adopted to step 14, and then Dde was removed with 2% hydrazine hydrate / DMF. Then, the method of compound 1 was continued to synthesize compound 23 (25 mg, purity 95%).

[0761] LCMS m / z=909.2[M / 2+H] + .

[0762] Example 24:

[0763] Using the above materials as raw materials, compound 24 (180 mg, purity 96%) was obtained by the method of compound 1.

[0764] LCMS m / z=996.2[M / 2+H] + ,664.6[M / 3+H] +.

[0765] Example 25:

[0766] Step 1: Using the above materials as raw materials, compound 25B was obtained by the method of compound 1.

[0767] Step 2: Add 30 ml of dichloromethane to a solid-phase synthesis reactor, followed by phenylsilane (1 g) and tetrakis(triphenylphosphine)palladium (462 mg), and react under nitrogen for 8 hours. Wash the resin with dichloromethane 5 times, N,N-dimethylformamide 5 times, and 0.5% sodium diethyldithiocarbamate solution in N,N-dimethylformamide for 15 min + 15 min, and then wash three times with N,N-dimethylformamide to obtain peptide resin 25C.

[0768] Step 3: 20% piperidine N,N-dimethylformamide solution was added to the reactor and reacted for 30 min. The mixture was washed with N,N-dimethylformamide solution 5 times, washed with methanol 3 times, and dried under vacuum to obtain peptide resin 25D (5 g).

[0769] Step 4: Add 50 ml of cleavage solution (2% trifluoroacetic acid + 98% dichloromethane) to a 100 ml reaction flask, stir well, then add peptide resin 25D (5 g), stir at room temperature for 0.5 hour, filter the resin to obtain a filtrate, and cleave the peptide resin again according to the above cleavage method. The filtrates obtained twice are collected, washed twice with water and once with saturated brine, dried over anhydrous sodium sulfate, and dried under vacuum to obtain compound 25E (2.3 g).

[0770] Step 5: Dichloromethane (1.2 L), compound 25E (2.3 g, 0.68 mmol), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (417.2 mg, 1.1 mmol), and DIEA (0.19 ml, 1.1 mmol) were added to a 2 L flask and reacted at room temperature for 16 h. MS showed that the reaction was basically completed. The product was extracted and washed twice with water and once with saturated brine, dried over anhydrous sodium sulfate, and dried under vacuum to obtain compound 25F (2.1 g).

[0771] Step 6: To a 100 ml reaction flask, add 60 ml of lysis buffer (91% trifluoroacetic acid + 4% triisopropylsilane + 3% 1,2-ethanedithiol + 2% water), stir thoroughly, then add compound 25F (2.1 g), and stir at room temperature for 2 hours. Filter the resin to obtain the filtrate, which is added to 600 ml of methyl tert-butyl ether (pre-cooled to 0°C). White flocculent material precipitates and is centrifuged (3 min at 3000 rpm). The white precipitate is washed three times with methyl tert-butyl ether and dried in vacuo to yield crude peptide 25G (1.2 g) as an off-white solid.

[0772] Step 7: To a 2L reaction flask, add water (1050ml), acetonitrile (450ml), and 25G (1.2g, 0.6mmol) in sequence. After stirring, slowly add iodine / acetonitrile solution (0.1mol / L) dropwise until the reaction solution turns pale yellow. Add ascorbic acid for quenching and purify by preparative HPLC. Separation method: 1. Apparatus: Waters 2767 preparative liquid chromatography; chromatographic column: SunFire@PrepC18 (19mm×250mm). 2. Filter the sample through a 0.45μm filter to prepare a sample solution. 3. Preparative chromatography conditions: a. Mobile phase A, B composition: A: 0.1% trifluoroacetic acid / H2O, B: CH3CN; b. Gradient elution: mobile phase content 5%-45%; c. Flow rate: 12ml / min; d. Elution time: 30min, retention time: 16min. Lyophilization yielded 25 as a white solid (80mg, 95% purity).

[0773] LCMS m / z=1010.9[M / 2+H] + 674.3[M / 3+H] + .

[0774] Example 26:

[0775] Using the above materials as raw materials, compound 26 (50 mg, purity 98%) was obtained by the method of compound 25.

[0776] LCMS m / z=1003.7[M / 2+H] + ,669.7[M / 3+H] + .

[0777] Example 27:

[0778] Using the above materials as raw materials, compound 27 (65 mg, purity 99%) was obtained by the method of compound 25.

[0779] LCMS m / z=1003.8[M / 2+H] + .

[0780] Example 28:

[0781] Using the above materials as raw materials, compound 28 (48 mg, purity 95%) was obtained by the method of compound 25.

[0782] LCMS m / z=988.8[M / 2+H]+ .

[0783] Example 29:

[0784] Using the above materials as raw materials, compound 29 (140 mg, purity 99%) was obtained by the method of compound 25.

[0785] LCMS m / z=1047.9[M / 2+H] + .

[0786] Example 30:

[0787] Using the above materials as raw materials, compound 30 (180 mg, purity 92%) was obtained by the method of compound 19.

[0788] LCMS m / z=1008.5[M / 2+H] + ,672.8[M / 3+H] + .

[0789] Example 31:

[0790] Using the above materials as raw materials, compound 31 (279 mg, purity 94%) was obtained by the method of compound 19.

[0791] LCMS m / z=1008.4[M / 2+H] + ,672.9[M / 3+H] + .

[0792] Example 32:

[0793] Using the above materials as raw materials, compound 32 (200 mg, 99%) was obtained by the method of compound 19.

[0794] LCMS m / z=1126.6[M / 2+H] + ,751.6[M / 3+H] + .

[0795] Example 33:

[0796] Using the above materials as raw materials, compound 33 (190 mg, 97%) was obtained by the method of compound 19.

[0797] LCMS m / z=1002.9[M / 2+H] + ,669.3[M / 3+H] + .

[0798] Example 34:

[0799] Using the above materials as raw materials, compound 34 (130 mg, purity 94%) was obtained by the method of compound 25.

[0800] LCMS m / z=1000.0[M / 2+H] + ,667.2[M / 3+H] + .

[0801] Example 35:

[0802] Using the above materials as raw materials, compound 35 (150 mg, purity 94%) was obtained by the method of compound 1.

[0803] LCMS m / z=1122.3[M / 2+H] + , 748.5[M / 3+H] + .

[0804] Example 36:

[0805] Using the above materials as raw materials, compound 36 (300 mg, purity 96%) was obtained by the method of compound 1.

[0806] LCMS m / z=805.0[M / 3+H] + .

[0807] Example 37:

[0808] Using the above materials as raw materials, the synthetic method of compound 1 was used to obtain compound 37 (100 mg, purity 95%)

[0809] LCMS m / z=948.5[M / 2+H] +

[0810] Example 38:

[0811] Using the above materials as raw materials, compound 38 (45 mg, purity 95%) was obtained by the method of compound 25.

[0812] LCMS m / z=981.7[M / 2+H] + .

[0813] Example 39:

[0814] Using the above materials as raw materials, compound 39 (110 mg, purity 97%) was obtained by the method of compound 1.

[0815] LCMS m / z=807.5[M / 3+H] + .

[0816] Example 40:

[0817] Using the above materials as raw materials, compound 40 (150 mg, purity 94%) was obtained by the method of compound 1.

[0818] LCMS m / z=996.4[M / 2+H] + ,664.7[M / 3+H] + .

[0819] Example 41:

[0820] Using the above materials as raw materials, compound 41 (150 mg, purity 97%) was obtained by the method of compound 1.

[0821] LCMS m / z=996.7[M / 2+H] + ,664.8[M / 3+H] + .

[0822] Example 42:

[0823] Using the above materials as raw materials, compound 42 (35 mg, purity 98%) was obtained by the method of compound 1.

[0824] LCMS m / z=996.2[M / 2+H] + ,664.5[M / 3+H] + .

[0825] Example 43:

[0826] Using the above materials as raw materials, compound 43 (95 mg, purity 97%) was obtained by the method of compound 10.

[0827] LCMS m / z=965.9[M / 2+H] + ,644.4[M / 3+H] + .

[0828] Example 44

[0829] Step 1: Using the above materials as raw materials, compound 44B was obtained by the method of compound 1.

[0830] Step 2: Add 30 ml of dichloromethane to a solid-phase synthesis reactor, followed by phenylsilane (1 g) and tetrakis(triphenylphosphine)palladium (462 mg), and react under nitrogen for 8 hours. Wash the resin with dichloromethane 5 times, N,N-dimethylformamide 5 times, and 0.5% sodium diethyldithiocarbamate solution in N,N-dimethylformamide for 15 min + 15 min, and then wash three times with N,N-dimethylformamide to obtain peptide resin 44C.

[0831] Step 3: Add 20% piperidine in N,N-dimethylformamide solution into the reactor and react for 30 min. Wash with N,N-dimethylformamide solution 5 times to obtain peptide resin 44D.

[0832] Step 4: N-methylpyrrolidone (20 ml), benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (417.2 mg, 1.1 mmol), and DIEA (0.19 ml, 1.1 mmol) were added to a solid-phase synthesis reactor and reacted at room temperature for 24 h. The mixture was monitored by ninhydrin to obtain a colorless state. The solvent was drained and the resin was washed with N,N-dimethylformamide 3 times, methanol 2 times, dichloromethane 1 time, and methanol 2 times. The peptide resin 44E / F (5 g) was obtained after vacuum drying.

[0833] Step 5: Add 40 ml of lysis buffer (91% trifluoroacetic acid + 4% triisopropylsilane + 3% 1,2-ethanedithiol + 2% water) to a 100 ml reaction flask, stir thoroughly, then add peptide resin 44E / F (5 g) and stir at room temperature for 2 hours. Filter the resin to obtain a filtrate, which is then added to 300 ml of methyl tert-butyl ether (pre-cooled to 0°C). A white flocculent solid precipitates and is centrifuged (3 min at 3000 rpm). The white precipitate is washed three times with methyl tert-butyl ether and dried under vacuum to obtain an off-white solid of crude peptide compound 44E / F (1.5 g). Purify by preparative HPLC. Separation Method: 1. Instrument: Waters 2767 Preparative HPLC; Column: SunFire@PrepC18 (19 mm × 250 mm). 2. Filter the sample through a 0.45 μm filter to prepare a sample solution. 3. Preparative Chromatography Conditions: a. Mobile phases A and B: A: 5 mmol / L ammonium acetate / H2O, B: CH3CN; b. Gradient elution: mobile phase content 5%-45%; c. Flow rate: 12 ml / min; d. Elution time: 30 min. Lyophilization afforded compounds 44-1 (77 mg, 94% purity, retention time 13.198 min) and 44-2 (44 mg, 98% purity, retention time 14.509) as white solids.

[0834] 44-1, LCMS m / z=903.8[M / 2+H] + ,603.0[M / 3+H] + .

[0835] 44-2, LCMS m / z=904.1[M / 2+H] + .

[0836] Example 45:

[0837] Using the above materials as raw materials, compound 45C (1.5 g) was obtained by the method of compound 1.

[0838] Step 3: In a 3 L reaction flask, water (750 ml), acetonitrile (750 ml), and 45C (1.5 g, 0.8 mmol) were added in sequence. After stirring, bismuth bromide (0.36 g, 0.8 mmol) was added and the pH was adjusted to 8 with ammonium bicarbonate. The reaction was allowed to proceed for 16 h before preparative HPLC purification. Separation method: 1. Apparatus: Waters 2767 preparative liquid chromatography; chromatographic column: SunFire@PrepC18 (19 mm × 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare a sample solution. 3. Preparative chromatography conditions: a. Mobile phase A, B composition: A: 0.1% trifluoroacetic acid / H2O, B: CH3CN; b. Gradient elution: mobile phase content 5%-45%; c. Flow rate: 12 ml / min; d. Elution time: 30 min, retention time: 17 min. Lyophilization afforded compound 45 (57 mg, 90% purity) as a white solid.

[0839] LCMS m / z=1047.1[M / 2+H] + ,698.5[M / 3+H] + .

[0840] Example 46:

[0841] Using the above materials as raw materials, compound 46 (105 mg, purity 92%) was obtained by the method of compound 1.

[0842] LCMS m / z=851.7[M / 3+H] + .

[0843] Example 47:

[0844] Compound 47 (320 mg, purity 95%) was synthesized using the above materials as raw materials using the method for compound 21.

[0845] LCMS m / z=818.9[M / 3+H] + ,614.5[M / 4+H] + .

[0846] Example 48:

[0847] Using the above materials as raw materials, compound 48 (200 mg, purity 97%) was obtained by the method of compound 1.

[0848] LCMS m / z=1049.7[M / 2+H] + , 833.7[M / 3+H] + .

[0849] Example 49:

[0850] Compound 49 (220 mg, purity 95%) was synthesized using the above-mentioned materials as raw materials using the method of compound 21.

[0851] LCMS m / z=1271.0[M / 2+H] + , 847.7[M / 3+H] + .

[0852] Example 50:

[0853] Using the above materials as raw materials, compound 50 (100 mg) was obtained by the method of compound 25.

[0854] LCMS m / z=1046.0[M / 2+H] + .

[0855] Example 51:

[0856] Using the above materials as raw materials, compound 51 (75 mg) was obtained by the method of compound 25.

[0857] LCMS m / z=1046.0[M / 2+H] + .

[0858] Example 52:

[0859] Using the above materials as raw materials, compound 52 (400 mg) was obtained by the method of compound 44.

[0860] LCMS m / z=935.5[M / 2+H] + ,623.9[M / 3+H] + .

[0861] Example 53:

[0862] Using the above materials as raw materials, compound 53 (72 mg) was obtained by the method of compound 25.

[0863] LCMS m / z=1049.6[M / 2+H] + ,700.2[M / 3+H] + .

[0864] Example 54:

[0865] Using the above materials as raw materials, compound 54 (400 mg) was obtained by the method of compound 1.

[0866] LCMS m / z=995.0[M / 2+H] + .

[0867] Example 55:

[0868] Using the above materials as raw materials, compound 55 (410 mg) was obtained by the method of compound 1.

[0869] LCMS m / z=982.0[M / 2+H] + .

[0870] Biological test methods

[0871] 1. IL-23α / IL-12β&IL-23R binding test

[0872] The TR-FRET method was used to test the inhibition of IL-23α / IL-12β & IL-23R binding by the compounds. Protein solutions of IL-23α / IL-12β (ACRO, Cat#ILB-H52W5) and IL-23R (ACRO, Cat#ILR-H82F3) were prepared in reaction buffer PPI (PerkinElmer, Cat#61DB10RDF). The final concentrations of IL-23α / IL-12β and IL-23R in the reaction mixture were 0.3 nM. The positive reference substance, Guselkumab, had a starting concentration of 30 nM, was diluted 3-fold, and had a 10-dose ratio. 0.1 μL of the diluted positive reference substance in the reaction buffer was transferred to a 384-well plate (Grenier, Cat#784075) using acoustic liquid delivery technology (Echo655) and centrifuged at 1000 rpm for 1 minute. 2.5 μL of the IL-23α / IL-12β solution was transferred to the 384-well reaction plate and centrifuged at 1000 rpm for 1 minute. The plate was incubated at 25°C for 60 minutes. 2.5 μL of the IL-23α / IL-12β solution was transferred to the plate. The IL-23R solution was transferred to a 384-well plate and centrifuged at 1000 rpm for 1 minute. 5 μL of the Streptavidin-Tb cryptate and Anti-6HIS-d2 detection mixture was transferred to a 384-well plate and centrifuged at 1000 rpm for 1 minute. The mixture was incubated at 25°C for 60 minutes. The HTRF signal (Ratio 665 / 620 nm) was read using a BMG High-Throughput Drug Screening Multi-Purpose Microplate Reader. IC values ​​were obtained using GraphPad Prism software. 50 Values ​​and nonlinear regression curve fitting.

[0873] Table 1

[0874] Conclusion: The compounds of the present invention, such as the compounds in the examples, have significant inhibitory ability on the binding of IL-23α / IL-12β and IL-23R.

[0875] 2. IL-23R reporter gene assay

[0876] The purpose of this experiment is to evaluate the ability of compounds to inhibit the binding of IL23p19 and IL23R in a reporter gene system. The HEK-blue IL23 reporter cell line (Invivogen, hkb-il23) was cultured in DMEM + 10% FBS + 100ug / mL Normocin medium. When the cell density reached 80%-90%, 5000 cells / well were plated into 384-well plates and cultured overnight at 37°C and 5% CO2. The compound stock solution was then diluted in DMSO and 40nL of the dilution was transferred to a 384-well culture plate by Echo. Incubate at 37°C and 5% CO2 for 0.5 hours. 40nL / well rhIL23 (R&D, 1290-IL) was added to the 384-well cell culture plate at a final concentration of 1ng / mL and incubated at 37°C and 5% CO2 for 24 hours. Add 18μL Quanti-Blue TM The solution was added to a new 384-well plate. 2 μL / well of cell culture supernatant was transferred to the 384-well plate prepared in step 6 and incubated at 37°C and 5% CO2 for 1 hour. The absorbance value was read on the BMG at 620-655 nM. The binding capacity of the compound was estimated using the following formula and the IC was fitted using GraphPad. 50 .

[0877] Inhibition rate calculation formula:

[0878] Average value of DMSO control group

[0879] Average value of group without IL23 stimulation

[0880] IC 50 The calculation formula is as follows:

[0881] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))

[0882] X: Compound concentration

[0883] Y: compound inhibition rate

[0884] Table 2 Inhibition of IL-23R by test compounds

[0885] Conclusion: The compounds of the present invention, such as the compounds in the Examples, have significant inhibitory ability on the binding between IL23p19 and IL23R.

[0886] 3. IL-23 stimulated pSTAT3 detection in PBMC

[0887] Cryopreserved human PBMCs were thawed and seeded onto plates pre-coated with CD3 antibody, with 1×10^6 cells per well. CD28 antibody was then added to the plates, and the cells were incubated at 37°C, 5% CO2 for 5 days. On the fifth day, after 4 hours of FBS starvation, the cells were seeded onto 96-well plates at a density of 100,000 cells per well. Diluted compounds were transferred to 96-well cell culture plates and incubated at 37°C, 5% CO2 for 1 hour. rhIL23 (R&D, 1290-IL) was added to the plates and incubated at 37°C, 5% CO2 for 30 minutes. Cells were lysed on ice for 30 minutes using lysis buffer containing 1× PHOSstop solution and centrifuged at 1000 rpm for 1 minute. The supernatant was then transferred to a 96-well ELISA plate and assayed for pSTAT3 using an ELISA kit (CST, 7300CA). The absorbance at 450 nM was read on a PHERAstar FSX (BMG LRBTECH). The inhibition rate of the compound was estimated using the following formula and the IC was fitted using GraphPad. 50 .

[0888] Inhibition rate calculation formula:

[0889] Average value of DMSO control group

[0890] Average value of group without IL23 stimulation

[0891] IC 50 The calculation formula is as follows:

[0892] Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)*HillSlope))

[0893] X: Compound concentration

[0894] Y: compound inhibition rate.

[0895] Table 3 pSTAT3 inhibition

[0896] Conclusion: The compounds of the present invention, such as the compounds in the examples, have a significant inhibitory effect on STAT3 phosphorylation.

[0897] 4. Pharmacokinetic test in mice

[0898] 4.1 Experimental Animals: Male Balb / c mice, 20-25 g, 18 mice per compound, purchased from Chengdu Dashuo Experimental Animal Co., Ltd.

[0899] 4.2 Experimental Design: On the day of the experiment, Balb / c mice were randomly divided into groups according to body weight. They were fasted but not watered for 12-14 hours before administration and fed 4 hours after administration.

[0900] Table 4. Dosing Information Note: Intravenous administration solvent: PBS; Oral administration solvent: PBS

[0901] Before and after drug administration, 0.06 mL of blood was collected via the orbital cavity under isoflurane anesthesia. The blood was placed in an EDTAK2 centrifuge tube and centrifuged at 5000 rpm at 4°C for 10 minutes to collect plasma. Blood was collected from both the intravenous and oral gavage groups at 0, 5, 15, 30 minutes, and 1, 2, 4, 6, 8, and 24 hours. All samples were stored at -80°C prior to analysis and quantitative analysis was performed using LC-MS / MS.

[0902] Table 5. Pharmacokinetic parameters of test compounds in mouse plasma -:not applicable.

[0903] Conclusion: The compounds of the present invention, such as the example compounds, have good pharmacokinetic characteristics in mice. For example, compounds 7, 16, and 24 have excellent pharmacokinetic characteristics in mice.

[0904] 5. Plasma stability test

[0905] In this study, plasma from five species, including humans, monkeys, dogs, rats, and mice, was used to evaluate the plasma stability of compound 7.

[0906] Plasma samples were prepared at a concentration of 1000 ng / mL and aliquoted into EP tubes at time points 0 and 6 hours. The 0-hour sample was directly added to an acetonitrile solution containing the internal standard, while the 6-hour sample was incubated at 37°C for the corresponding time and then added to an acetonitrile solution containing the internal standard. LC-MS / MS was used to determine the concentration of the test substance in the samples. The residual rate was calculated from the ratio of the peak area of ​​the test substance and the internal standard in the time point sample to the peak area of ​​the zero-time sample.

[0907] Experimental results: Under the test conditions, when the concentration level was 1000 ng / mL, the residual rate of the test compound was shown in Table 6 below.

[0908] Table 6 Residual rate (%) after 6 hours at 37℃

[0909] 6. Gastrointestinal fluid stability test

[0910] 1. Solution Preparation

[0911] 1.1 Preparation of dilute hydrochloric acid: Measure 23.4 ml of hydrochloric acid and dilute it to 1000 ml with water.

[0912] 1.2 Preparation of artificial gastric juice: Take 1.64 ml of dilute hydrochloric acid, add about 80 ml of water and 1 g of pepsin, shake well, and dilute with water to 100 ml.

[0913] 1.3 Prepare 0.1 mol / L NaOH: weigh 0.4 g of NaOH and dissolve it in 100 ml of water.

[0914] 1.4 Preparation of artificial intestinal fluid: Take 0.68g of potassium dihydrogen phosphate, add 50ml of water to dissolve it, and adjust the pH value to 6.8 with 0.1mol / L sodium hydroxide solution; take 1g of pancreatic enzyme, add appropriate amount of water to dissolve it, mix the two liquids, and dilute with water to 1000ml.

[0915] 2. Sample Preparation

[0916] Take about 12.5 mg of the sample and put it into a 25 ml volumetric flask. Add artificial gastric juice (or artificial intestinal juice) to dissolve and dilute to the scale line.

[0917] 3. Analytical methods

[0918] Instrument model: Agilent 1260 Infinity; Mobile phase A: 10 mmol / L K2HPO4; Mobile phase B: acetonitrile; Column: Phenomenex Gemini @ 3um C18 150 x 4.6 mm; wavelength: 224 nm; column temperature: 30°C; sample tray temperature: 37°C; injection time: 35 min; injection volume: 10 μl; injection method: gradient injection; gradient method. The gradient mobile phase is shown in Table 7.

[0919] Table 7 Gradient mobile phase

[0920] Sample concentration: 0.5 mg / ml

[0921] 4. Sampling, testing and results

[0922] Sampling and testing: First test the blank solution (artificial gastric juice or artificial intestinal juice), then take the prepared sample (freshly prepared before use) and put it into the injection tray for immediate injection, and then inject a sample at 4.5h, 9.5h, and 18h ​​respectively.

[0923] The test results are shown in Table 8.

[0924] Table 8 Gastrointestinal fluid stability

[0925] Conclusion: Compound 7 has good stability in artificial gastrointestinal fluid.

Claims

1. A cyclic peptide compound, a stereoisomer thereof, or a pharmaceutically acceptable salt or solvate or dimer thereof, wherein the peptide compound has an amino acid sequence of formula (I): Xa1 - Xa2-Xa3-Xa4-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Xa 11 -Xa 12 -Xa 13 (I) wherein Xa1 and Xa6 are each independently selected from Pen, Pcn, Asn, Ala, Ala (3-amino), Ala (2-ethyne), Ala (3-azido), Ala (2-ethene), Val (2-ethene), Asp, 2,4-diaminobutyric acid, Ser, Cys, Hcys, Glu, and the residues of Xa1 and Xa6 react to form a peptide ring or form a cyclic peptide via L1; Xa2 is selected from Asn, His, or an analog of Asn or His; Xa3 is selected from Thr or an analog of Thr; Xa4 is selected from Trp or an analog of Trp; Xa5 is selected from Lys, Gln, Arg, Cit, or an analog of Lys, Gln, Cit, Arg; Xa7 is selected from Phe or an analog of Phe; Xa8 is selected from Phe, Trp, 2-Nal, or an analog of Phe, Trp, or 2-Nal; Xa9 is selected from Thp or an analog of Thp; XA 10 Selected from Glu, Cys, or analogs of Glu and Cys; XA 11 Selected from Asn, Lys, or analogs of Asn, Lys; XA 12 Selected from 3-Pal, Phe, Asp, or analogs of 3-Pal, Phe, Asp; XA 13 Selected from Sarc or an analog of Sarc; Alternatively, Xa1, Xa2, Xa3, Xa4, Xa5, Xa7, Xa8, Xa9, Xa 10 , Xa 11 , Xa 12 , Xa 13 Any amino acid residues in are directly condensed or linked via L1 to form one or more peptide rings; L1 is selected from W1-RL -W2; R L Select from key, C 1-6 Alkylene, C 2-4 Alkenylene, C 2-4 Alkyne, 3-6 membered cycloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 6-10 membered aryl, -(OCH2CH2) a -, the alkylene, alkenylene, alkynylene, cycloalkyl, heterocycloalkyl, heteroaryl, aryl may be further substituted by 1-4 R L1 replace; a is any integer selected from 0-10; R L1 are independently selected from halogen, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 1-4 Alkoxy, 3-6 membered cycloalkyl, COOH, NH2, -NH-C(=O)-C 1-4 Alkyl, wherein the alkyl, alkoxy, cycloalkyl group is optionally further substituted by 1-4 substituents selected from halogen, CN, OH and NH2; W1 and W2 are each independently selected from a bond, C 1-6 Alkylene, -O-, -S-, -NR W1 -、-CONR W1 -、-NR W1 CO-, -C(=O)O- or -OC(=O)-, wherein one or more -CH2- in the alkylene group is optionally replaced by 1 to 4 groups selected from -O-, -S-, -NR W1 - or -CO-, the alkylene group is optionally further substituted by 1-4 groups selected from halogen, =O, C 1-4 Alkyl, halogenated C 1-4 Substitution of alkyl, CN, OH and NH2; R W1 Selected from H, C 1-4 Alkyl, halogen; and the peptide compound is optionally linked to a protecting group; The protecting group is selected from Ac, glutaryl, succinyl, NH2 or OH; Alternatively, the peptide is reacted with reactive groups Xa1, Xa6, Xa 10 Separated by covalent bonds formed with the molecular scaffold to form a polypeptide ring containing at least two rings; Alternatively, the peptide compound is optionally conjugated with a modifying group at Xa1, Xa5 or Xa7; The condition is that the peptide compound is not selected from the following structures: (Ac)Pen-Asn-Thr-Trp(CH3)-Lys(Ac)-Pen-Phe[4-(2-aminoethoxy)]-[2-Nal]-Thp-Glu-Asn-[3-Pal]-Sarc(NH2), wherein a disulfide bond is formed between Pen and Pen.

2. The peptide compound according to claim 1, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the peptide compound has an amino acid sequence of formula (II) or formula (II-1): (Ac)Xa1-Xa2-Thr-Xa4-Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Asn-(3-Pal)-Sarc(NH2) (II) (Ac)Xa1-Xa2-Thr-Xa4-Lys(Ac)-Xa6-Xa7-Xa8-Xa9-Glu-Asn-(3-Pal)-Sarc(NH2) (II-1)(SEQ ID NO.1) in, The residues Xa1 and Xa6 react to form a peptide ring or are linked via L1 to form a peptide ring.

3. The peptide compound according to claim 1, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the peptide compound has an amino acid sequence of formula (III) or formula (III-1): (Ac)Xa1-Xa2-Thr-Trp(R1)Xa5-Xa6-Xa7-Xa8-Xa9-Xa 10 -Asn-(3-Pal)-Sarc(NH2) (III) (Ac)Xa1-Xa2-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-Xa8-Xa9-Glu-Asn-(3-Pal)-Sarc(NH2) (III-1) (SEQ ID NO.2) in, The residues of Xa1 and Xa6 react to form a peptide ring or form a cyclic peptide via L1; And the residues of Trp (R1) and Xa5 are directly condensed or linked via L1 to form a peptide ring; Or the residues of Trp (CH3) and Lys (Ac) can be directly condensed or linked via L1 to form a peptide ring; or Xa1, Xa6, Xa 10 Forming a bicyclic peptide with the molecular scaffold; R1 is selected from H, C 1-4 Alkyl, C 3-6 Cycloalkyl, 4-8 membered heterocycloalkyl, the alkyl, cycloalkyl, heterocycloalkyl optionally further substituted by 1-4 selected from halogen, =O, C 1-4 Alkyl, halogenated C 1-4 Substituents include alkyl, CN, OH and NH2.

4. The peptide compound according to claim 1, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the peptide compound has an amino acid sequence of formula (IV), formula (IV-1) or formula (V): (N-terminal) Xa1-Asn-Thr-Trp(R1)-Xa5-Xa6-Xa7-(2-Nal)-Xa9-Xa 10 -Xa 11 -Xa12 -Sarc(C-terminal) (IV) (N-terminal)Xa1-Asn-Thr-Trp(CH3)-Lys(Ac)-Xa6-Xa7-(2-Nal)-Xa9-Glu-Xa 11 -Xa 12 -Sarc(C-terminal) (IV-1)(SEQ ID NO.3) (N-terminal)Xa1-His-Thr-Trp(R1)-Xa5-Xa6-Xa7-(2-Nal)-Xa9-Xa 10 -Xa 11 -Xa 12 -Sarc(C-terminal) (V) in, The residues of Xa1 and Xa6 react to form a peptide ring or are linked via L1 to form a peptide ring; the presence or absence of protecting groups at the N-terminus and C-terminus; Or N-terminal conjugated modifying group; 2-Nal and Xa 12 The residues are linked by L1 to form a peptide loop; and / or Xa9 vs Xa 12 The residues are linked by L1 to form a peptide loop; and / or Lys(Ac) and Xa7 residues are linked via L1 to form a peptide ring; and / or Xa7 vs Xa 11 The residues are linked by L1 to form a peptide loop; and / or The residues of 2-Nal and Glu are linked via L1 to form a peptide ring; and / or The residues Xa1 and Glu are linked via L1 to form a peptide ring; and / or Xa1 and Xa 11 The residues are linked by L1 to form a peptide loop; and / or Xa1 and Xa 10 The residues are linked by L1 to form a peptide loop; and / or The residues of 2-Nal and Sarc are linked to form a peptide ring via L1; and / or Xa9 and Sarc residues are linked via L1 to form a peptide loop; and / or XA 11 The residues of Sarc are linked via L1 to form a peptide loop; and / or The residues of Xa1, Sarc and Glu are linked via L1 to form a peptide ring; and / or or Xa1, Xa6, Xa 10 Forming a bicyclic peptide with the molecular scaffold; R1 is selected from C 1-2 Alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, wherein the alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl is optionally further substituted with 1-4 substituents selected from F, Cl, Br, =O, methyl, ethyl, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2F, -CHF2, -CF3, CN, OH and NH2; The conditions are: (1) when Xa1 at the N-terminus is linked to other amino acid residues via L1, the N-terminus protecting group does not exist; (2) When the C-terminal Sarc is linked to other amino acid residues through L1, the C-terminal protecting group does not exist.

5. The peptide compound according to claim 1, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein: The residues of Xa1 and Xa6 react to form a peptide ring or form a cyclic peptide through L1, and Xa4 and Xa5, Xa1 and Xa 10 , Xa8 and Xa 10 , Xa8 and Xa 12 , Xa8 and Xa 13 , Xa9 and Xa 13 , Xa5 and Xa7, Xa 11 With Xa 13 , Xa1 and Xa 11 , Xa7 and Xa 11 One or two groups of residues in the peptide ring are directly condensed or linked via L1 to form a peptide ring; or Xa1, Xa6, Xa 10 Forms a bicyclic peptide with the molecular framework.

6. The peptide compound according to claim 1, its stereoisomers or pharmaceutically acceptable salts or solvates or dimers thereof, wherein the peptide compound is a dimer compound, and the dimer compound is formed by connecting the peptide compound and the amino acid residues in the peptide compound through a polyethylene glycol chain; the polyethylene glycol chain is n is any integer selected from 0-99.

7. The peptide compound according to claim 1, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the modifying group is p is selected from any integer of 0-50, and q is selected from any integer of 0-50.

8. The peptide compound according to any one of claims 1 to 7, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein The residues Xa1 and Xa6 react to form the following structure: Wherein the * end is the Xa1 end, Xa1 and Xa2 are connected through the * position, and the NH2 end is connected to a protecting group or the NH2 end is conjugated with a modifying group; Xa2 is selected from Asn, His, or an analog of His, wherein the analog of His is selected from Xa3 is selected from Thr; Xa4 is selected from the group consisting of Trp analogs selected from Xa5 is selected from Lys, Gln, Arg, Cit, or an analog of Arg or Lys, wherein the analog of Arg or Lys is selected from Alternatively, the Xa5 residue is conjugated to a modifying group; Xa7 is selected from Phe or an analog of Phe selected from Alternatively, the Xa7 residue is conjugated to a modifying group; Xa8 is selected from Phe, Trp, 2-Nal, or analogs of Phe, Trp and 2-Nal; the analogs of Phe, Trp and 2-Nal are selected from Xa9 is selected from Thp or an analog of Thp selected from XA 10 Selected from Glu or Cys; XA 11 Selected from Asn or Lys; XA 12 Selected from 3-Pal or Phe; The molecular framework is selected from:

9. The peptide compound according to claim 1, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein L1 is selected from a bond, vinyl, propenyl, butenyl, -O-(CH2) r -O-(CH2) r -NH-C(=O)-, -O-(CH2) r -O-(CH2) r -、-O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -、-C(=O)-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-C(=O)-, -NH-C(=O)-, -C(=O)-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-C(=O)-(CH2) r -、-(CH2) r -O-(CH2) r -、-O-(CH2) r -NH-, C 1-6 Alkylene, -C(=O)-, -C(=O)-(CH2) r -NH-, -(CH2) r -O-(CH2) r -NH-, -O-(CH2) r -O-(CH2) r -O-(CH2) r -O-(CH2) r -NH-, -(CH2) r -NH-, -C(=O)-(CH2) r -O-(CH2) r -NH-, -(CH2)r -NH-C(=O)-(CH2) r -、-C(=O)-(CH2)-(OCH2CH2) a -NH-; r is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; a is selected from 3, 4, 5 or 6.

10. The peptide compound according to claim 1, its stereoisomer or its pharmaceutically acceptable salt or solvate or dimer, wherein the peptide compound is selected from one of the structures in Table 1.

11. A pharmaceutical composition comprising the peptide compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and / or excipient.

12. Use of the peptide compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, or the pharmaceutical composition according to claim 11, in the preparation of a medicament for preventing and treating a disease or condition in which IL-23 is overexpressed in a diseased tissue of a subject.

13. The use according to claim 12, wherein the disease or condition in which IL-23 is overexpressed comprises inflammatory bowel disease, Crohn's disease and psoriasis.

14. A pharmaceutical composition or pharmaceutical preparation comprising 1-1500 mg of the peptide compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and / or excipient.

15. A method for treating a disease in a mammal or a human, the method comprising administering to a subject a therapeutically effective amount of a peptide compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, the therapeutically effective amount preferably being 1-1500 mg, the disease preferably being inflammatory bowel disease, Crohn's disease and psoriasis.